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ABSTRACT 
 
Mulibrey nanism is a developmental disorder with autosomal recessive inheritance. It 
is characterized by prenatal onset growth failure without postnatal catch-up growth, 
distinctive craniofacial features, progressive cardiopathy and failure of sexual 
maturation. Besides the developmental features, the patients develop insulin 
resistance syndrome and type 2 diabetes at an early age and they have an increased 
risk of developing tumors. Mulibrey nanism is a rare disorder, with less than 120 
patients reported worldwide. As 80% of all diagnosed patients come from Finland, 
mulibrey nanism is a classical example of a disorder belonging to the Finnish disease 
heritage. The molecular pathogenesis underlying this disorder is unknown. 
Prior to this study, the gene underlying mulibrey nanism was positionally 
cloned in the year 2000 and identified as a novel member of the RBCC (RING-B-
Box-coiled-coil) protein family. In 2001 the gene was given its present name, 
TRIM37, when the tripartite motif (TRIM) protein family was characterized. In 2002, 
mulibrey nanism was classified as a peroxisomal disorder when the TRIM37 protein 
was shown to localize to peroxisomes.  
The physiological function of TRIM37 and the pathogenetic mechanisms 
leading from TRIM37 dysfunction to the mulibrey nanism phenotype remain 
unknown. However, while this study was ongoing TRIM37 was shown to possess 
ubiquitin E3 ligase activity and thus possibly mediate ubiquitin dependent protein 
degradation, suggesting that accumulation of yet unknown substrate proteins may 
underlie the disease pathogenesis. 
In this study, the TRIM37 gene was characterized in detail. Besides 
characterization of the complete genomic structure of the gene, a transcription 
initiation window, with several separate transcription start sites, was identified and the 
putative promoter region immediately upstream of the transcription initiation window 
was shown to possess basal promoter activity. Further, several alternative splice 
variants of the gene were identified, including a highly expressed testis specific 
variant, encoding an identical protein product with the main transcript. Expression of 
TRIM37 mRNA was detected in several different tissues, with highest expression seen 
in testis and in brain, when the expression patterns of the two major transcripts in 
different human tissues were studied by quantitative real-time PCR.  
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Several mulibrey nanism patients of different ethnic backgrounds were studied 
and thirteen novel mutations in TRIM37 were found. While most mutations predict 
truncation of the protein products and most likely lead to mRNA degradation, three 
novel mutations predict translation of mutated proteins (p.Cys109Ser, p.Gly322Val 
and p.Glu271_Ser287del). These three mutations were further shown to result in 
altered subcellular localization of the mutant proteins. All the TRIM37 mutations 
identified to date predict loss-of normal function alleles, and thus no genotype-
phenotype correlation is seen among the patients. 
In order to fully understand the pathogenetic mechanisms leading from 
TRIM37 dysfunction to the mulibrey nanism phenotype, an animal model for the 
disorder is needed. For the development of a Trim37 knock-out mouse, the mouse 
Trim37 gene that is highly homologous to the human gene was studied in detail. The 
genomic organization was characterized and alternative splice variants, including a 
testis specific variant predicting a longer protein product, were identified. Further, the 
expression of Trim37 was studied in detail in developing and adult mouse tissues and 
a restricted and cell specific pattern was detected by immunohistochemical methods. 
This thesis work provides new tools for the molecular diagnosis of mulibrey 
nanism as well as for the further study of TRIM37 function and the pathogenetic 
mechanisms behind this interesting disorder. 
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INTRODUCTION 
 
In the early 1990’s a significant number of researchers were working towards 
identification of the genes behind a group of disorders overrepresented in Finland. 
This group, comprising 36 monogenic disorders, is called the Finnish disease heritage.  
The definition is somewhat ambiguous and whether some diseases should be included 
or not is under debate. However, essential to the group is that even though the 
diseases are rare, a considerably higher incidence is seen in the Finnish population 
than in other populations, due to the population history of Finland and founder effects 
(Norio, 2003a). Mulibrey nanism, a growth disorder associated with abnormalities in 
several organs, is one of the best examples of these diseases, with nearly 90 patients 
known in Finland and less than 30 patients reported elsewhere in the world (Karlberg 
et al., 2004a). 
Now more than ten years later, after countless hours of work and aided by the 
data of the human genome project, the genes behind most of the disorders of the 
Finnish disease heritage have been identified and the underlying mutations 
characterized (Norio, 2003b). However, the molecular mechanisms leading from the 
dysfunctional genes to the disease phenotypes still remain unknown in many cases. 
To tackle the interesting question of how a certain mutation in a certain gene can lead 
to the phenotype seen in patients is not easy. To identify the pathogenetic mechanisms 
and biological pathways behind a disorder, detailed information on the dysfunctional 
gene and its protein product are needed. Important information includes, for example, 
the normal physiological function of the protein, the biological pathways the protein 
is involved in, when and where it is expressed and how the expression is regulated, 
what other proteins interact with the protein in question and how the disruption affects 
them. Knowledge of the gene and protein structure and the type of mutations that 
underlie the disease can shed some light on these questions, and some hypotheses 
based on these data can be tested with cellular models. However, sometimes the only 
way to answer these questions is through an animal model.  
The laboratory mouse, Mus musculus domesticus, is the principle mammalian 
species used as a model for human biology in biomedical research. Lower species, 
like worms, flies and fish, have their advantages, but the level of genetic homology 
and the similarities in embryogenesis make the mouse the most used model organism 
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for human diseases. Currently, the mouse germ line can be manipulated in almost 
every conceivable way through genetic modification of mouse ES cells, there are 
large scale mutagenesis programs that produce thousands of new mouse mutants 
every year, and the mouse genome sequence is available in public databases. These 
facts will assure that the mouse will most likely keep its position as the number one 
animal to model human disease also in future decades. However, mice and humans 
are not identical and even high homology between human and mouse orthologs does 
not ensure that the mouse model will replicate the human phenotype. 
To successfully generate a mouse model by targeted disruption of a specific 
gene, detailed information of the gene of interest should be available. Important 
questions to be answered include: will the disruption of the gene in question disrupt 
other genes or regulatory regions affecting other genes, are there alternative splice 
variants that may still produce functional proteins and is the gene expressed in the 
same tissues in mouse and man. Frequently a mouse model is designed to mimic a 
human mutation, however, this does not necessarily overcome the possible problems 
mentioned above.  
Apart from the characterization of the human TRIM37 gene and the mutations 
underlying mulibrey nanism, one aim of this study was to establish the foundation for 
the generation of Trim37 knock-out mice.  Characterization of the mouse Trim37 gene 
and the distribution of Trim37 expression in developing and adult mouse tissues was 
the first step in this process, which is currently ongoing. The first homozygous 
Trim37 knock-out mice have just been born and in the future they will hopefully help 
to elucidate the pathogenetic mechanisms behind mulibrey nanism. 
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REVIEW OF THE LITERATURE 
 
1. Growth retardation 
Variation in human height is fairly large and even seemingly unusual growth patterns 
can be regarded as within the normal range. For example, in familial short stature the 
children are short merely because their parents are short, and temporarily slow growth 
with catch-up growth compensating for final height is typical for late puberty 
(Rosenthal and Wilson, 1994). 
Abnormal short stature is considered when a persons height is 2.5 standard 
deviation (SD) below the mean height for age and gender or for midparental height 
(Rosenthal and Wilson, 1994). Growth is dependent on several different factors and 
whether pre- or postnatal, abnormal short stature can be due to either primary i.e. 
intrinsic factors that work from inside the cells, or secondary factors i.e. extrinsic 
factors that originate from the environment.  
 
1.1 Prenatal growth retardation 
The World Health Organization defines ’low birth weight’ as below 2500 g. About 
15% of all infants are born with low birth weight (Unicef statistics 2005), and the 
level is twice as high in developing countries as it is in developed regions. However, 
this term is irrespective of gestational age and includes babies born prematurely. 
Small for gestational age (SGA), on the other hand, takes into account the gestational 
age and describes infants with birth size below a certain centile, normally the 10th, 
meaning that at birth 10% of the population at that gestational age are smaller while 
90% are bigger. Intrauterine growth restriction (IUGR) is defined as the failure of the 
infant to achieve his or her growth potential in utero. Thus, in IUGR the failure to 
grow along the consistent centile is more important than the absolute size of the infant 
(Ergaz et al., 2005). 
Prenatal growth is a complex, dynamic process, tightly linked to cell 
proliferation, differentiation and organization of different organ systems. These events 
are controlled by a variety of genetic and environmental factors that can be divided 
according to maternal, placental or fetal origin. Maternal factors leading to prenatal 
growth restriction include exposure to toxic substances (for example smoking, 
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alcohol, drugs), chronic diseases, malnutrition, birth order, multiple births and 
maternal genetic factors. Placental factors affecting fetal growth include mainly 
placental insufficiency, which can be the result of vascular damage, pre-eclampsia, 
placental infarction, partial placental separation or simply a small placenta. Genetic 
and chromosomal aberrations, as well as intrauterine infection, are fetal factors behind 
IUGR (Rosenthal and Wilson, 1994; Ergaz et al., 2005). 
 IUGR can be either symmetric or asymmetric. Head-to-abdominal 
circumference ratios can be used to differentiate infants into proportionally small i.e. 
symmetrical, or those with relative head sparing (asymmetrical). Symmetrical IUGR 
is often due to fetal causes for example viral infections or developmental 
abnormalities, in which case all the organs show equal growth restriction. 
Asymmetrical IUGR, on the other hand, is usually due to extrinsic factors for example 
placental insufficiency or teratogenic substances. When suffering from malnutrition, 
the fetus tries to prioritize organs and maintain normal growth in the brain, while 
other organs are left behind (Cunnigham et al., 1997).  
IUGR infants show 12 times higher perinatal mortality than do infants with 
normal birth weight (Cunnigham et al., 1997). Later in life, even after postnatal catch-
up growth, they are still at greater risk of developing coronary heart disease, 
hypertension and type 2 diabetes (Reece and Hagay, 1999; Barker et al., 2005). 
 
1.2 Postnatal growth retardation 
Failure to thrive is a condition where an infant grows more slowly than expected. In 
most cases, the underlying problem is inadequate nutrition, but it may also be a 
symptom of another problem such as a viral infection or digestive problem. Chronic 
diseases, endocrine abnormalities, for example growth hormone deficiency or 
hypothyroidism, and genetic disorders such as Turner syndrome are other causes for 
postnatal growth retardation (Rosenthal and Wilson, 1994; Cowell, 1995; Ergaz et al., 
2005). 
 
1.3 Congenital growth disorders 
A strong association between chromosome aberrations, IUGR and congenital 
malformations exists (Monk and Moore, 2004). For example, fetuses with trisomies 
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are frequently growth restricted, and many chromosome abnormalities include 
suboptimal growth of the fetus as one of the major hallmarks. Some studies have 
reported abnormal fetal karyotype to be responsible for one in five of all IUGR 
fetuses (Snijders et al., 1993).  
Most of the congenital growth disorders are due to abnormal growth and 
remodeling of bone and/or cartilage (Baitner et al., 2000). These disorders, called 
chondro- or osteochondrodysplasias, are often hereditary and mutations for example 
in fibroblast growth factor receptors, collagens, different hormone receptors and 
sulfate transporters have been shown to underlie them (Baitner et al., 2000). The 
major clinical sign in these disorders is short stature with disproportionately short 
extremities, but many patients also manifest other features that often require medical 
attention (Baitner et al., 2000). Achondroplasia (OMIM# 100800), which is caused by 
mutations in FGFR3 (Fibroblast Growth Factor Receptor 3), is the most common 
human chondrodysplasia (Shiang et al., 1994). Diastrophic dysplasia (OMIM# 
222600) and Cartilage-hair hypoplasia (OMIM# 250250) are congenital bone and 
cartilage disorders enriched in the Finnish population and represent disorders of the 
Finnish disease heritage (Norio, 2003b). 
Several other monogenic disorders manifest proportional short stature as a 
major landmark of the disorder. For example, Silver-Russell syndrome (SRS, OMIM# 
180860) shows severe pre- and postnatal growth retardation. Other clinical features of 
SRS include asymmetry of the limbs and craniofacial disproportion (Silver et al., 
1953; Russell, 1954). The majority of SRS cases are sporadic but some familial cases 
have been reported (Duncan et al., 1990; Ounap et al., 2004). Further, approximately 
10% of all SRS cases are associated with maternal uniparental disomy of chromosome 
7 (Hannula et al., 2001; Monk et al., 2002).  
Another disorder with similar phenotype is the 3-M syndrome (OMIM# 
273750). 3-M syndrome is characterized by low birth weight, proportional dwarfism, 
dysmorphic facial features and radiological abnormalities (Miller et al., 1975). 
Interestingly, the gene behind 3-M syndrome was recently identified as cullin-7, 
encoding CUL7 that assembles an E3 ubiquitin ligase complex and thus promotes 
ubiquitination (Huber et al., 2005). Cul7-/- mice die immediately after birth due to 
respiratory distress, and show progressive growth retardation during their embryonic 
period. Abnormal vascular morphogenesis is seen in the Cul7-/- placentas and dermal 
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and hypodermal hemorrhage is detected in mutant embryos, suggesting vascular 
morphogenesis as one of the underlying causes for the growth problem in 3-M 
syndrome (Arai et al., 2003). Together with the results that TRIM37 underlying 
mulibrey nanism (see section 2) encodes a ubiquitin E3 ligase (Avela et al., 2000; 
Kallijärvi et al., 2005), these data suggest that impaired ubiquitination may play a role 
in intrauterine growth restriction in humans.   
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2. Mulibrey nanism 
Mulibrey nanism (Muscle-Liver-Brain-Eye nanism; OMIM# 253250) is a rare 
prenatal onset growth disorder with autosomal recessive inheritance. It was first 
described in Finland in the 1970’s by Jaakko Perheentupa (Perheentupa et al., 1970; 
Perheentupa et al., 1973), and has also been known as Perheentupa syndrome. To date 
there are approximately 120 patients diagnosed with mulibrey nanism worldwide, 
with the majority of them (~90) from Finland. However, sporadic patients with 
mulibrey nanism have been reported from various ethnic groups around the world 
(Thoren, 1973; Cumming et al., 1976; Voorhess et al., 1976; Similä et al., 1980; 
Sanchez-Corona et al., 1983; Cotton et al., 1988; Haraldsson et al., 1993; Seemanova 
and Bartsch, 1999; Avela et al., 2000; Jagiello et al., 2003). 
 The clinical picture of a mulibrey nanism patient can be variable. Due to this, 
and the overlap of the phenotype with other growth disorders, the diagnosis is 
sometimes difficult. Overlapping phenotypic features with mulibrey nanism are seen 
for example in Silver-Russell and 3-M syndromes (see previous section 1.3). 
 
2.1 Mulibrey nanism – a member of the Finnish disease heritage 
The Finnish disease heritage is a group of rare monogenic diseases comprising 36 
different disorders that are more common in Finland than elsewhere in the world 
(Norio, 2003a). The reason why some hereditary diseases are overrepresented in 
Finland, while some that are relatively common in other populations are extremely 
rare or absent in the Finnish population, lies in the population history of Finland 
(Norio et al., 1973; de la Chapelle, 1993). A small and restricted number of founders, 
national and regional isolation, as well as several population bottlenecks have lead to 
enrichment of some disease alleles while others have been eliminated from the 
genomes of Finns. Thus, these disorders all have one or two founder mutations 
enriched in the isolated Finnish population that account for the majority of the cases 
inside Finland (Norio, 2003a).  
Mulibrey nanism is a perfect example of a disease belonging to the Finnish 
disease heritage. It is clearly more common in Finland than elsewhere, most of the 
Finnish patients come from clustered regions in Savo and North Carelia (Lipsanen-
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Nyman, 1986; de la Chapelle, 1993), and in the Finnish patients there is one major 
mutation accounting for 98% of all Finnish disease chromosomes (Avela et al., 2000).  
 
2.2 Clinical characteristics of mulibrey nanism 
The most characteristic feature of mulibrey nanism is prenatal onset growth 
restriction, without postnatal catch-up growth. The mean height is -3.1 SD at birth and 
-4.0 SD at the age of diagnosis, and the adult height of mulibrey patients is on average 
33 cm below the mean adult height in the population (Karlberg et al., 2004a). Further, 
the patients are gracile and have thin extremities. Over 90% of the patients show 
typical craniofacial features including triangular face with prominent forehead, low 
nasal bridge and scaphocephaly (Figure 1). Other typical findings include J-shaped 
sella turcica, peculiar high voice, hepatomegaly, yellowish dots in the ocular fundi, 
cutaneous naevi flammei, and fibrous dysplasia of long bones (Karlberg et al., 2004a).  
 
 
Figure 1. A boy with mulibrey nanism at the age of 8 months and 5 years.  
The typical craniofacial features; triangular face, frontal bossing, low nasal bridge and the 
low-set ears are evident at the age of 8 months. At the age of 5 years they are still seen, but 
are not as striking as before. The pictures are published with informed consent from the 
patient and his parents. 
 
REVIEW OF THE LITERATURE  19   
The most severe and sometimes life threatening symptoms are due to the heart 
disease, constituting pericardial constriction and myocardial hypertrophy (Lipsanen-
Nyman et al., 2003; Kivistö et al., 2004). Even though the patients show enlarged 
brain ventricles, they manifest no signs of intellectual incapacity, and the only 
neurological abnormality is mild muscular hypotonicity and mild delay in motor and 
speech development (Karlberg et al., 2004a). Hypoplasia of various endocrine glands 
causing hormonal deficiency and hypogonadism, as well as premature ovarian failure 
with subfertility, have been reported in the patients (Lipsanen-Nyman, 1986; Karlberg 
et al., 2004b). The main clinical features of the Finnish mulibrey nanism patients are 
listed in Table 1. 
 
Table 1. Summary of the features in 85 Finnish mulibrey nanism patients at the time of 
diagnosis. (Karlberg et al., 2004a; Karlberg et al., 2004b; Karlberg et al., 2005)  
Feature  Frequency (%) 
Thin extremities 99 
Short stature 96 
Small, high voice 96 
General gracility 95 
Characteristic facial features  90 
J-shaped sella turcica 89 
Scaphocephaly 81 
Hypoplastic tongue 80 
Yellowish dots in the ocular fundi 79 
Muscular hypotonicity 68 
Cutaneous naevi flammei 65 
Feeding difficulties during infancy 50 
Hepatomegaly 45 
Fibrous dysplasia of long bones 25 
Renal anomaly 18 
Skeletal asymmetry 15 
Congestive heart failure 12 
Pericardial constriction 6 
Metabolic syndrome (in adults): 70 
 - fatty liver  100 
 - hypertension 81 
 - type 2 diabetes 50 
 - impaired glucose tolerance (IGT) 42 
 - high fasting insulin values 90 
 - overweight 42 
Tumors:  
 - fibrothecomas (in adults) 55 
 - liver tumors  7 
 - Wilms' tumor 4 
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The clinical diagnosis of mulibrey nanism can be challenging since growth restricted 
infants are a very heterogeneous group and the clinical features of mulibrey nanism 
are not unique but are also seen in other diseases. The diagnostic criteria of mulibrey 
nanism summarized by Karlberg and co-workers (Karlberg et al., 2004a) are shown in 
Table 2. 
 
Table 2. Diagnostic criteria of mulibrey nanism. 
For the diagnosis three major signs with one minor or two major signs with three minor are 
required. Adapted from Karlberg et al., 2004a. 
Diagnostic sign 
Major signs 
  Growth restriction (A, B or C) 
     A) SGA lacking catch-up growth 
     B) Childhood height 2.5 SDS below  mean 
     C) Adult height 3.0 SDS below mean 
  Characteristic radiological findings (A or B) 
     A) slender long bones with thick cortex and narrow medullar channels 
     B) J-shaped sella turcica 
  Characteristic craniofacial features 
     Scaphocephaly, triangular face, high and broad forehead, low nasal bridge and telecanthus 
  Characteristic ocular findings 
     Yellowish dots in retinal midperipheral region 
  Mulibrey nanism in a sibling 
Minor signs 
  Peculiar high voice 
  Hepatomegaly 
  Cutaneous naevi flammei 
  Fibrous dysplasia of long bones 
 
 
Mulibrey nanism patients have an increased risk of developing tumors. Liver tumors 
have been observed in six of 85 Finnish patients (Karlberg et al., 2004a) and twelve of 
22 postpubertal Finnish female patients have been diagnosed with benign ovarian 
tumors i.e. fibrothecomas (Karlberg et al., 2004b). Association of mulibrey nanism 
with childhood kidney tumors (i.e. Wilms’ tumor) has also been reported, as Wilms’ 
tumor has earlier been seen in three Finnish and one Czech patient (Seemanova and 
Bartsch, 1999; Karlberg et al., 2004a). Additionally, three patients included in this 
study have had Wilms’ tumor. Interestingly, several genetic conditions that manifest 
excessive growth, for example Beckwith-Wiedeman syndrome (OMIM #130650), 
also have an increased risk for Wilms’ tumor (Sotelo-Avila et al., 1980). 
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2.3 Metabolic findings in mulibrey nanism 
Mulibrey nanism patients develop severe insulin resistance and metabolic syndrome 
at a very young age. While in childhood the patients show normal glucose and insulin 
levels, over 90% of the adults show either type 2 diabetes (50%) or impaired glucose 
tolerance (IGT; 42%), and the symptoms become evident at young adult life 
(Karlberg et al., 2005). Nearly half of the adult patients are obese and fatty liver is 
seen in all adult patients and in nearly half of the prepubertal children. Further, 
hypertension has been observed in 81% of the adults and 70% of the adult patients 
fulfill the criteria for the metabolic syndrome (Karlberg et al., 2005).  
Metabolic syndrome is a collection of metabolic risk factors present in one 
person. These include abdominal obesity, atherogenic dyslipidemia, hypertension and 
insulin resistance or glucose intolerance (Hansen, 1999). Metabolic syndrome poses a 
major public health problem in western countries, since it leads to increased risks for 
coronary heart disease, vascular disease, stroke and diabetes (Zimmet et al., 2005). 
One of the underlying processes is insulin resistance. Insulin, a hormone secreted by 
the β-cells of the pancreas, enables cells to utilize glucose. Insulin resistance is a 
condition where cells do not respond to the normal amount of insulin and thus the 
pancreas produces additional insulin, resulting in high insulin levels. When cells do 
not respond even to high levels of insulin, the result is type 2 diabetes (Fletcher and 
Lamendola, 2004; Ten and Maclaren, 2004). 
 A risk for insulin resistance syndrome (IRS) has been associated with SGA 
(Veening et al., 2003). SGA is often due to an unfavorable environment during the 
fetal period causing the fetus to adapt to poor nutrition. After birth, with ample supply 
of nutrients, most SGA children show extensive postnatal weight gain and the risk for 
IRS correlates with this weight gain (McMillen and Robinson, 2005). In mulibrey 
nanism patients the growth retardation is not due to the fetal environment, the patients 
do not manifest extensive prepubertal weight gain, and the postpubertal weight gain 
they do manifest does not correlate with the IRS (Karlberg et al., 2005).  On the other 
hand, the early development of fatty liver and elevated serum leptin levels suggest 
that the accumulation of fat in the liver may be critical for the development of IRS 
and metabolic syndrome in mulibrey nanism (Karlberg et al., 2005).   
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 Overall, the metabolic phenotype of the patients makes mulibrey nanism an 
excellent monogenic model for type 2 diabetes, insulin resistance and metabolic 
syndrome (Karlberg et al., 2005).   
 
2.4 TRIM37 mutations – the primary defect in mulibrey nanism 
A positional cloning strategy was initiated in the early 1990s to identify the causative 
gene for mulibrey nanism. As in many other disorders of the Finnish disease heritage, 
this strategy turned out to be successful also for mulibrey nanism, and in the year 
2000 the underlying gene was identified when four different mutations in mulibrey 
nanism patients were identified in a cDNA sequence (KIAA0898; 4111 bp, predicting 
a 964 aa protein) coding for a novel member of the RING-B-Box-Coiled-Coil 
(RBCC) protein family (Avela et al., 2000).  At that time the gene was named MUL 
refering to mulibrey nanism, but it was later renamed TRIM37, when the TRIM 
protein family was characterized and the TRIM37 protein was included in this family 
(Reymond et al., 2001).   
Prior to this study, five mutations in TRIM37 had been described in mulibrey 
nanism patients (Avela et al., 2000; Jagiello et al., 2003). They all produce premature 
termination codons (PTCs) and thus predict truncation of the protein product. The 
major Finnish mutation, present in 98% of all Finnish disease chromosomes, is an A 
to G transition on the 3’ splice acceptor sequence of intron 6 (c.493-2A>G; Avela et 
al., 2000). This results in activation of a cryptic splice site five nucleotides 
downstream of the actual splice site and deletion of five nucleotides from the resulting 
mRNA transcript. The carrier frequency of this mutation is relatively high in the high-
risk region of Finland (Savo and North-Carelia), where nine of 217 control persons 
(1:24) were shown to carry the disease allele (Avela et al., 2000). The other Finnish 
mutation, a 1-bp deletion (c.2212delG), was seen in two patients that are compound 
heterozygotes for this and the Finnish major mutation (Avela et al., 2000).  No 
carriers of this mutation were detected in 316 control individuals (Avela et al., 2000). 
 Apart from the two Finnish mutations, three mutations in TRIM37 had been 
identified in patients of non-Finnish origin. A Czech patient showed a homozygous 5-
bp deletion (c.838_842delACTTT), and a homozygous 1-bp insertion (c.1346dupA) 
was seen in an American patient (Avela et al., 2000). A splice-site mutation affecting 
the 3’ splice acceptor site of intron 9 (c.810-1G>A), leading to deletion of 8 
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nucleotides from the mRNA transcript, was reported in a Turkish family (Jagiello et 
al., 2003). Interestingly, phenotypic heterogeneity is seen in this family with three 
affected members. While one of them presents the typical clinical findings of 
mulibrey nanism, her two siblings are more severely affected and have additionally 
mental retardation (Jagiello et al., 2003). However, since all three siblings share the 
same mutation and mental retardation has not been reported in any other mulibrey 
nanism patients, it is likely that other genetic factors play a role in the mental 
retardation seen in this inbred family. 
 All five mutations lead to premature termination codons, and predict 
truncation of the protein products. The lengths of the putative truncated polypeptides 
vary significantly, with the Finnish major mutation predicting a 175 amino acid (aa) 
protein, with only the RING and B-Box motifs present, and the other Finnish 
mutation predicting a 769 aa protein with all the functional domains present in the 
truncated polypeptide (Avela et al., 2000). However, since PTCs induce mRNA decay 
through nonsense surveillance and NMD (Losson and Lacroute, 1979), truncated 
proteins are rarely produced and instead the truncating mutations behave as loss-of-
function alleles by accelerating mRNA degradation and reducing mRNA quantity 
(Culbertson, 1999; Holbrook et al., 2004). This is most likely also true for the 
TRIM37 mutations with PTCs. 
While this study was ongoing a third Finnish mutation, c.227T>C, in TRIM37 
was identified in a mulibrey nanism patient (Kallijärvi et al., 2005). This mutation, 
observed in compound heterozygote form with the Finnish major mutation, leads to 
substitution of leucine by proline at aa position 76 (p.Leu76Pro) between the RING 
and B-box motifs of the TRIM domain. The mutation was further shown to affect the 
ubiquitin ligase activity of the mutated protein (Kallijärvi et al., 2005). 
According to Northern blot analysis, TRIM37 mRNA is widely expressed in adult 
human tissues (Avela et al., 2000). In RNA in situ hybridization studies expression of 
TRIM37 is detected in multiple tissues during human and mouse embryogenesis. A 
subset of neural crest derived tissues, including dorsal root and trigeminal ganglia, 
show intense expression of TRIM37, and high expression is seen also in liver and in 
epithelia of ectodermal or endodermal origin of several organs whose development is 
regulated by mesenchymal-epithelial interactions (Lehesjoki et al., 2001).  
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3. The TRIM protein family 
The Tripartite Motif family of proteins (TRIM), is characterized by the presence of a 
RING finger, one or two zinc-chelating motifs named B-boxes and a coiled-coil 
region (Reymond et al., 2001). Thus, it was previously named the Ring-B-Box-
Coiled-Coil (RBCC) family of proteins. The order and spacing between the domains 
in the tripartite motif are conserved (Figure 2), suggesting that the tripartite motif is 
an integrated functional structure rather than a collection of separate domains (Meroni 
and Diez-Roux, 2005). While a RING finger is present in a variety of proteins, the B-
box is the critical determinant of a tripartite motif. A few members of the TRIM 
protein family do not have RING domains but are still considered as members of the 
family because the other motifs follow the conserved order and spacing of TRIM 
proteins (Meroni and Diez-Roux, 2005). The TRIM domain is invariably located in 
the N-terminus, while various additional domains may be present in the C-terminus of 




Figure 2. Schematic presentation of the domain structure of the TRIM family members. 
 
 
The RING domain is defined by ordered arrangement of cysteine (C) and histidine  
(H) residues that bind two zinc atoms (Freemont, 1993). The other zinc-binding motif, 
the B-box, occurs as two types; B-box 1 and B-box 2. They share a similar but 
distinct pattern of C and H residues (Borden et al., 1993; Reymond et al., 2001). If 
both are present in a TRIM protein, the type 1 B-box always precedes the type 2 B-
box, and if only one B-box is present it is always type 2 (Reymond et al., 2001). The 
cysteine-rich zinc binding motifs of the TRIM domain, the RING and the B-box, are 
believed to mediate protein-protein interactions (Borden, 1998). The coiled-coil 
domain that follows the type 2 B-box is also involved in interactions, promoting 
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formation of large protein complexes and possibly being the domain responsible for 
multimerization of TRIM proteins (Reymond et al., 2001). The primary sequence of 
the coiled-coil region is not conserved, only the hydrophobic aas (often leucines) that 
are required for the distinctive folding of the motif, i.e. coiling, are present at 
conserved positions (Lupas, 1996). 
 
3.1 The RING finger family of E3s 
The RING finger is a cysteine-rich zinc-binding sequence motif with conserved 
spacing of the zinc ligands (Freemont, 1993). RING fingers are defined by a 
consensus sequence, CX2CX9-39CX1-3HX2-3C/HX2CX4-48CX2C, and they can be 
classified into two categories, RING-HC and RING-H2, depending whether the fifth 
zinc-binding residue is cysteine (–HC) or histidine (-H2) (Joazeiro and Weissman, 
2000). Initially, the RING finger motif was thought to function only in the 
dimerization of proteins, but several reports have shown that it plays a critical role in 
mediating ubiquitin transfer from the ubiquitin conjugating enzyme to its substrates, 
and thus acts as a ubiquitin E3 ligase. How this is accomplished is unknown. 
Regulation of the E3 ligase activity of the RING finger proteins is achieved through 
phosphorylation or interaction with other proteins (Joazeiro and Weissman, 2000). 
There are two different types of RING finger E3s. A single-subunit RING E3 
consists of solely the RING finger protein, while in a multisubunit RING E3 the 
RING finger is part of a functional multiprotein complex (Pickart, 2001a). The RING 
finger E3s regulate a diverse set of cellular functions. They have a role in the cell 
division cycle (Joazeiro and Weissman, 2000), they have been implicated in 
tumorigenesis and metastasis (Fang et al., 2003) and they can contribute to apoptosis 
(Yang et al., 2000).  
Despite the great variety of cellular processes in which the TRIM proteins are 
involved, the conserved integrated modular structure suggests a general function for 
the TRIM domain and thus a common biochemical function for all TRIM proteins. As 
the RING domain is strongly associated with ubiquitin E3 ligase activity and E3 
activity has also been reported for some TRIM proteins (Joazeiro and Weissman, 
2000), it has been proposed that TRIM proteins may represent a novel class of single 
protein RING finger ubiquitin E3 ligases (Meroni and Diez-Roux, 2005).  
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3.1.1 Ubiquitin dependent protein degradation 
In order for a cell to survive, it has to be able to quickly recognize and remove 
misfolded or otherwise abnormal proteins. For example, regulation of the cell cycle is 
highly dependent on protein degradation (Glotzer, 1995). One mechanism to mark 
proteins for degradation is ubiquitination.  
Ubiquitin, a small 76 aa protein, is highly conserved. Human, mouse and 
Drosophila ubiquitins show 100% homology in their aa sequence, and even yeast 
ubiquitin shows 96% homology to mammalian ubiquitin. The high evolutionary 
conservation implies an essential role for ubiquitin in all organisms, and yeast studies 
have proven ubiquitin essential for cell viability (Finley et al., 1994). All known 
functions of ubiquitin are mediated through its conjugation to other proteins, where it 
serves as a signaling molecule. Interpretation of the ubiquitin signal depends on the 
topology of the linkage and the number of linked ubiquitin molecules. 
Monoubiquitination serves as an intracellular sorting signal for internalizing 
membrane proteins or targeting proteins for endocytosis (Hicke, 1999; Hicke and 
Dunn, 2003), while a polymer of ubiquitins targets proteins for proteasomal 
degradation (Hershko and Ciechanover, 1998). Besides signaling for proteasomal 
degradation, polyubiquitination has been shown to activate phosphorylation (Pickart, 
2001b). The ubiquitin chain can be formed by linkage through different lysine 
residues of ubiquitin. Usually Lys48-linked polyubiquitin chains target proteins for 
proteasomal degradation, while Lys63-linked ubiquitins regulate endocytosis and 
lysosomal sorting (Weissman, 2001).  
The formation of the polyubiquitin chain to the substrate proteins requires the 
sequential action of three different enzymes (Figure 3). In the first step of this process, 
ubiquitin is activated in an ATP-dependent manner by the E1 enzyme. A single 
ubiquitin activating enzyme E1 is present in most organisms, including yeast and 
humans, and as ubiquitin is essential for life so is the E1 enzyme (McGrath et al., 
1991). The activated ubiquitin is then transferred from E1 to the next enzyme in the 
cascade, the E2 conjugating enzyme (Hochstrasser, 1996).  
Ubiquitin E3 ligase is the component of the ubiquitin conjugation pathway 
most directly involved with substrate specificity.  However, it is also the least well-
understood factor of the ubiquitin system. An E3 ligase is defined as an enzyme that 
binds, directly or indirectly, specific protein substrates and promotes the transfer of 
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ubiquitin from the E2 conjugating enzyme to the substrate protein or another ubiquitin 
on a polyubiquitin chain. Several different E3s, each recognizing a unique set of 
substrates, work in conjunction with a single or a few E2s (Hershko and Ciechanover, 
1998). The E3s can be classified into two distinct families according to the catalytic 
domain they utilize, namely the hect domain E3s and the RING-finger family of E3s 
(Huibregtse et al., 1995; Deshaies, 1999). In both families, the E3 ligase binds both 
the substrate and the E2, and positions them so that the activated ubiquitin can be 
transferred from E2 to a lysine residue of the substrate protein (Hershko et al., 1983). 
Recently, additional types of E3s, such as U-box ubiquitin ligases, have been 
identified (Hatakeyama and Nakayama, 2003) and a subfamily of E3 ligases have 
been shown to also ubiquitinate non-lysine residues (Cadwell and Coscoy, 2005).  
 
 
Figure 3. An overview of the ubiquitin conjugation pathway. 
A ubiquitin-activating enzyme (E1) first activates ubiquitin in an ATP-dependent reaction. 
The activated ubiquitin then binds to ubiquitin conjugating enzyme (E2), which acts in 
conjunction with a ubiquitin E3-ligase. The E3-ligase binds to the protein substrates and 
promotes the transfer of ubiquitin from the E2 to the substrate creating a polyubiquitin chain 
and targeting the substrate protein for degradation or regulating lysosomal sorting or 
endocytosis. Adapted from Gao and Karin 2005.  
 
The organization of the ubiquitin conjugation cascade is hierarchic. Whereas in most 
eukaryotes there is a single E1 enzyme, there are at least 13 E2 enzymes in yeast, and 
it’s estimated that mammals might have as many as 60 different E2s (Hochstrasser, 
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1996; Gao and Karin, 2005). A vast number of E3s are present in all organisms, only 
a fraction of which have been identified thus far (Pickart, 2001a). As the E3s play a 
critical role in selecting the substrates, regulation of either the catalytic activity or the 
substrate interaction properties of the E3s allows the best degree of selectivity as well 
as the regulation of effectiveness of the ubiquitin cascade. Phosphorylation of either 
the substrate or the E3 have been shown to regulate ubiquitination (Gao and Karin, 
2005).  
Ubiquitinated proteins are in a dynamic state. They are either subject to further 
rounds of ubiquitination, ubiquitin removal by deubiquitinating enzymes or 
degradation by the 26S proteasome (Hochstrasser, 1996; Wilkinson, 2000). The 26S 
proteasome is a multisubunit complex that breaks down proteins into peptides and 
recycles ubiquitin. It belongs to the family of self-compartmentalized proteases, with 
regulatory units containing several ATP-dependent chaperones, and a cylindrical core 
proteinase (20S proteasome) capped by the regulatory units at both ends. The 
ATPases presumably help unfold the substrates and move them through the narrow 
pore leading to the proteolytic active sites (Baumeister et al., 1998). The substrates for 
proteasomal degradation are recognized through polyubiquitin chains (Pickart, 
2001b).  
 
3.2 TRIM proteins in disease 
The TRIM family proteins are involved in a multitude of cellular processes, including 
apoptosis, cell cycle regulation, tumorigenesis and viral response. Consequentially, 
TRIM proteins are associated with several different pathological conditions varying 
from rare mendelian disorders to cancer and viral infections (Meroni and Diez-Roux, 
2005).  
Mendelian disorders resulting from mutations in TRIM proteins include, for 
example, familial mediterranean fever (FMF; OMIM# 249100), which is due to 
mutations in TRIM20, also known as Pyrin. FMF is an inflammatory disorder 
characterized by recurrent attacks of fever and polyserositis (Consortium, 1997a; 
Consortium, 1997b). Pyrin is an atypical TRIM protein as it lacks the RING domain. 
However, the organization of other motifs is typical for a TRIM domain and thus it is 
considered as a member of the TRIM protein family (Reymond et al., 2001). The 
function of this protein is as yet unknown. On the other hand, TRIM18, also known as 
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Midin, underlies X-linked Opitz syndrome (OS; OMIM# 300000), a complex 
congenital disease affecting mainly ventral midline development (Quaderi et al., 
1997; De Falco et al., 2003).  The MID1 gene encodes a RING finger E3 ligase that 
ubiquitinates protein phosphatase 2A (PP2A), and the pathological phenotype is due 
to the diminished proteolysis of PP2A (Trockenbacher et al., 2001).  
Changes in the expression of TRIM proteins are seen in different pathogenic 
conditions. For example, TRIM32, another TRIM protein with ubiquitin E3 ligase 
activity, is associated with skin carcinogenesis and is highly expressed in skin derived 
tumors (Horn et al., 2004). Further, some TRIM family members have been shown to 
be involved in innate cellular responses to viral infection. For example, TRIM5 has a 
splice form, TRIM5α, which was shown to restrict HIV-1 infection in Old World 
Monkey cells, suggesting that TRIM5 may recognize and ubiquitinate the HIV capsid 
and target it for degradation (Stremlau et al., 2004).  
 
3.3  The TRIM37 protein 
The TRIM37 gene underlying mulibrey nanism encodes a member of the TRIM 
protein family. In TRIM37, the N-terminal TRIM domain is followed by an internal 
TRAF (tumor necrosis factor (TNF) receptor associated factor) domain, and the C-
terminal part of the protein has no known functional domains (Figure 4) (Avela et al., 
2000).  However, two aspartate-glutamate-serine (DES)-rich sequences are located in 
the C-terminal part of TRIM37, but apart from a weak homology to several 
transcriptional regulators, these have no known functions (Avela et al., 2000). 
Classical TRAF family proteins are involved in TNF receptor signaling. They serve as 
adaptor proteins for a wide variety of cell surface receptors, possibly by linking the 
cytosolic domain of the receptor to downstream protein kinases or ubiquitin ligases, 






Figure 4. A schematic presentation of TRIM37.  
The functional domains and the DES-rich regions are shown. Two adjacent nuclear 
localization signals are present at the position marked with NLS. 
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Unlike classical TRAF family proteins, in TRIM37 the TRAF domain is located in 
the central region of the protein rather than the C-terminal end. TRIM37 has been 
shown to be capable of binding to the classical TRAF family proteins and itself via its 
TRAF domain (Zapata et al., 2001). 
 
3.3.1 TRIM37 localizes to peroxisomes  
Two adjacent nuclear localization signals are present in the TRIM37 sequence, 
predicting nuclear localization for the protein (Figure 4). In immunofluorescence 
studies, however, both endogenous and ectopically expressed TRIM37 localize, at 
least partially, to peroxisomes classifying mulibrey nanism as a peroxisomal disorder 
(Kallijärvi et al., 2002). No known peroxisomal targeting signals are present in 
TRIM37, so the localization may be dependent on interaction partners. The coiled-
coil region of the TRIM domain has been shown to be critical and sufficient to 
localize TRIM proteins to their correct subcellular compartments (Reymond et al., 
2001). This is most likely also true for TRIM37, as mutant TRIM37 resulting from 
the Finnish major mutation that disrupts the coiled-coil region loses the peroxisomal 
localization, while the mutant protein resulting from the Finnish minor mutation with 
an intact TRIM domain targets correctly to peroxisomes (Kallijärvi et al., 2002). 
Interestingly, the TRIM proteins have been shown to interact with themselves and the 
coiled-coil region is necessary and sufficient for this interaction (Reymond et al., 
2001). Since coiled-coil regions also mediate oligomerization of proteins in general 
by selective heterodimerization (Lupas, 1996), it may well be responsible for the 
peroxisomal localization of TRIM37 by interacting with an as yet unidentified protein 
that targets to peroxisomes.  
Peroxisomes are single membrane-bound organelles that participate in a wide 
variety of metabolic processes in eukaryotic cells. An interesting property of 
peroxisomes is that their size, number, protein content and physiological function are 
adjusted according to the cell’s metabolic and developmental state (Johnson and 
Olsen, 2001). Apart from their role in lipid metabolism and hydrogen peroxide 
detoxification, peroxisomes have also been shown to function in intracellular 
signaling and in regulating developmental processes (Titorenko and Rachubinski, 
2004).  
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Improper assembly of peroxisomes results in metabolic or developmental 
defects and lethality or severe disease (Wanders, 2004). In general, peroxisomal 
disorders are divided into two subgroups including disorders of peroxisome 
biogenesis (PBD), in which the peroxisome is not formed properly, and single 
peroxisomal enzyme deficiencies (Wanders, 2004). Some examples of peroxisomal 
disorders are listed in table 3.  
 Mulibrey nanism shares several symptoms with other peroxisomal disorders, 
in particular with the PBDs. These include short stature, facial dysmorphism, retinal 
pigmentary changes, muscular hypotonicity and hepatomegaly (Karlberg et al., 
2004a). However, the neurological phenotype is remarkably milder in mulibrey 
nanism than it is in most peroxisomal disorders with no notable changes in 
intelligence and only mild structural defects present in the central nervous system 
(CNS) (Karlberg et al., 2004a).  
 
Table 3. Examples of peroxisomal disorders.  
The Zellweger syndrome and rhizomelic chondrodysplasia punctata are PBDs while the X-
linked adrenoleukodystrophy and rhizomelic chondrodysplasia punctata type 2 are single 















multiple congenital anomalies,  
patients rarely survive the first 
year of life 






PEX7 short stature,  
typical facial features,  
severe mental retardation 
Agamanolis and Novak, 1995 
Braverman et al., 1997 
Motley et al., 1997 




ABCD1 neurodegenerative disorder, 
accumulation of very-long-
chain fatty acids in plasma and 
tissues 
 
Mosser et al., 1993 
Gartner et al., 1998 
Moser et al., 2000 
Rhizomelic 
Chondrodysplasia 
Punctata type 2 
(222765) 
DHAPAT short stature,  
developmental delay 
 
Wanders et al., 1992 
Ofman et al., 1998 
 
 
3.3.2 TRIM37 has ubiquitin E3 ligase activity 
The physiological function of TRIM37 is unknown. However, as for some other 
members of the TRIM protein family, autoubiquitination and formation of poly-
ubiquitin chains has also been reported for TRIM37, suggesting that it acts as a 
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ubiquitin E3 ligase. Thus, it may be involved in proteasomal protein degradation or 
signaling (Kallijärvi et al., 2005). No substrate proteins for TRIM37 are known, and 
the identification of these would be important as the accumulation of these substrate 
proteins may underlie the pathogenetic mechanisms behind mulibrey nanism. 
TRIM37 is highly insoluble, and when overexpressed it forms aggregates that have 
been characterized as aggresomes (Kallijärvi et al., 2005). Aggresomes are aggregates 
of nondegraded proteins that form in the pericentriolar region when the production of 
misfolded proteins exceeds the capacity of the proteasomal degradation machinery 
(Johnston et al., 1998). Thus, the accumulation of overexpressed TRIM37 to 
aggresomes suggests that TRIM37 may itself be degraded through the proteasome 
pathway. 
TRIM37 is the first peroxisomal ubiquitin E3 ligase identified in mammals, 
and whether ubiquitin exists inside peroxisomes is not known. However, in yeast a 
peroxisomal membrane protein, Pex4p, acts as a ubiquitin conjugating enzyme (Crane 
et al., 1994) and recently ubiquitin dependent localization and recycling between 
peroxisomes and the cytosol was reported for a yeast Pex20p protein (Leon et al., 
2006). Whether the ubiquitin E3 ligase activity of TRIM37 is a peroxisomal function 
is not known. 
Insulin signaling is a transitory effect that needs rigorous control in order for 
the cells to maintain their homeostasis (Rome et al., 2004). Correct levels of different 
signaling molecules are important for proper insulin action, and altered levels of key 
molecules have been associated with type 2 diabetes and other insulin related 
pathologies. The levels of these signaling molecules are controlled by their synthesis 
and degradation rates. The ubiquitin-proteasome pathway is one of the major 
proteasomal degradation pathways, and has been suggested to affect the regulation of 
the insulin signaling cascades and insulin action at several levels (Rome et al., 2004). 
Thus, as TRIM37 has ubiquitin E3 ligase activity, and loss-of-function mutations 
result in IRS, it is tempting to speculate that TRIM37 might have a role in regulating 
insulin signaling.  
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4. Regulation of gene expression 
Expression of mammalian genes can be regulated on spatial and temporal levels. 
Some genes are expressed essentially in all cell types and at all times. These genes are 
called housekeeping genes and often encode proteins required for essential and 
general functions of a cell. However, some genes show very restricted expression 
patterns and are expressed only in a specific tissue, in some individual cells, at a 
specific developmental stage or at specific times of the cell cycle (Strachan and Read, 
2003). For example, during development and embryogenesis coordination and tight 
regulation of gene expression is essential for proper division and differentiation of 
individual cells. Expression has to be up or down regulated during certain critical 
periods or above or below certain critical thresholds for the proper developmental 
processes to occur and give rise to the specialized tissues and organs of an organism 
(Gilbert, 2000). Further, for some genes the default stage is inactive and an inducer is 
needed for their expression. Ectopic expression, i.e. expression in an improper place 
or at improper time, can have devastating effects, thus tight regulation of timing, 
location and level of expression are essential for several genes (Strachan and Read, 
2003).  
Control mechanisms regulating gene expression are highly conserved among 
different species. In prokaryotes, two major levels of gene regulation have been 
described, one at the chromatin level and the other involving RNA polymerase. First 
of all, for a gene to be expressed the DNA has to be accessible. In its normal state, 
DNA is tightly packed around a set of histones, resulting in a condensed inaccessible 
state. Before a gene can be transcribed this condensed form has to be unraveled. 
Histone modifications, methylation, acetylation, phosphorylation and ubiquitination 
play a crucial role in controlling chromatin condensation (Berger, 2002). When the 
DNA is accessible, RNA polymerase can then catalyze the DNA-dependent synthesis 
of mRNA, and the specificity and effectiveness of the polymerase regulate the rate of 
mRNA synthesis. Analogous but more complex mechanisms work in eukaryotes, and 
some additional control mechanisms have been observed in mammals (Kornberg, 
1999). 
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4.1 Transcriptional control  
Several different mechanisms regulate mammalian gene expression at the 
transcriptional level and the major control point of gene regulation occurs at the 
initiation of transcription (Young et al., 2002). 
When the DNA is accessible, co-operation of several different factors are 
needed for transcription to start. The cis–acting promoter is one of the major 
elements. The core promoter region, located near the transcription initiation site, 
contains the basal promoter elements which bind proteins that belong to the general 
transcription machinery. Upstream from the transcription initiation site are the 
positive or negative proximal promoter elements, namely enhancers or silencers. 
Trans-acting sequence specific activator- and repressor- proteins bind to these specific 
sequences and either increase or decrease the basal expression level. Further away 
from the core promoter region are the distal enhancer elements that can be located 
thousands of base pairs away from the actual gene they are regulating. The general 
transcription machinery that contains RNA polymerase II and general transcription 
factors is sufficient to promote basal gene transcription (Goodrich et al., 1996), and 
recruitment and binding of these elements to the promoter region as well as the 
effectiveness of the polymerase are major players in initiating transcription (Young et 
al., 2002). However, several sequence-specific transcription factors and different co-
regulatory proteins are required for efficient transcription and for specific regulation 
of expression (Orphanides and Reinberg, 2002; Woychik and Hampsey, 2002). 
 
4.2 Translational control  
Translation of mRNA into a protein is the final step in the gene expression pathway, 
and regulation of translation is one mechanism to control gene expression (Gebauer 
and Hentze, 2004). Translational control can have much more rapid effects on the 
protein level than does transcriptional control, and can thus be used to fine-tune 
protein levels. Although most of the regulation of gene expression takes place at the 
transcriptional level, translational control is crucial especially in early embryogenesis 
and also at later developmental stages including, for example, sex determination 
(Kuersten and Goodwin, 2003). Global control of translation that affects all 
translation occurring at a specific time in a specific cell is mainly achieved through 
modification of translation initiation factors. Gene specific regulation, on the other 
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hand, is driven by regulatory protein complexes or mRNA molecules that bind to 
specific sequences, usually present at the 5’ or 3’ untranslated regions (UTR) of these 
genes (Gebauer and Hentze, 2004). Thus, regulatory sequences and structural features 
of the mRNA are responsible for its translational fate. The cap structure and the 
polyA tail are strong promoters of translation initiation, upstream open reading frames 
(uORFs) often reduce translation of the main ORF, and several secondary or tertiary 
structures, for example hairpins, normally block translation initiation. Most of the 
regulatory elements discovered so far are inhibitory, implying that mRNAs are 
translationally active by default (Gebauer and Hentze, 2004). 
The 3’ UTR is a major functional part of the mRNA responsible for 
translational regulation (Kuersten and Goodwin, 2003; de Moor et al., 2005). The 
length of the polyA tail has an effect on translation as long polyA tails correlate with 
translation, while short polyA tails correlate with repression of translation (de Moor et 
al., 2005). Different control elements in the 3’ UTRs also regulate turnover rates and 
localization of mRNAs in cells (Kuersten and Goodwin, 2003; Parker and Song, 
2004). 
Translational regulation can also occur through small microRNAs (miRNAs), 
which bind specific sequences at the 3’ UTRs and repress translation (Filipowicz et 
al., 2005). Recently, the use of small interfering RNAs (siRNAs) has proven to be an 
effective method of repressing translation experimentally. However, there is a 
functional difference between endogenous miRNAs and synthetic siRNAs, based on 
the degree of complementarity. While miRNAs bind by incomplete base-pairing, 
siRNAs have a perfect match to the target mRNA and repress translation by 
degrading mRNA (Hutvagner and Zamore, 2002; Filipowicz et al., 2005).  
 
4.2.1 Translational control in germline  
Formation of the germ cell lineage is critical for survival of a species. Germ cells are 
the only cells that contribute genetically to the next generation and they are the only 
cells undergoing meiosis and recombination. Thus, integrity of the germ cell genome 
is extremely important. Precise timing and regulation of expression of a wide variety 
of genes is essential for mammalian meiosis and germ cell development, and this is 
mainly achieved through translational control (Eddy and O'Brien, 1998). The 
regulation can be positive, allowing translation of proteins necessary for germ cell 
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specification, or negative, repressing translation of proteins promoting somatic fate 
(Leatherman and Jongens, 2003).  
Many genes have atypical patterns of expression during meiosis. Some of the 
developmentally regulated genes are transcribed exclusively in germ cells and some 
genes that are also expressed in somatic cells produce germ cell specific transcripts 
(Eddy and O'Brien, 1998). For example, a RING finger protein, RNF4, has a testis-
specific transcript present specifically in spermatids. The transcript encodes a protein 
product identical to that present in other tissues but differs from the major transcript 
only in the 3’ untranslated region. This testis specific RNF4 transcript is 
translationally repressed and only a small fraction of it is translated (Pero et al., 2003). 
 
4.3 Naturally occurring antisense RNAs 
Natural antisense RNAs are endogenous transcripts with complementary sequences to 
other transcripts named sense transcripts. Most are cis-encoded, that is, encoded from 
the same locus and transcribed from opposite strands. In contrast to cis-encoded 
transcripts that display perfect complementarity to sense transcripts, trans-encoded 
antisense transcripts may show only partial complementarity, since they are 
transcribed from a different locus (Vanhee-Brossollet and Vaquero, 1998).  
Antisense transcripts were first identified in prokaryotes, where they serve as a 
mechanism to regulate gene expression (Wagner and Simons, 1994). Recent studies 
have shown that the presence of naturally occurring antisense RNAs is a common 
feature also in the human genome (Lehner et al., 2002; Yelin et al., 2003), and 
growing evidence for coupled, balanced or unbalanced, expression of counterpart 
genes indicates a role for antisense transcripts in regulating expression of their sense 
counterpart genes in humans (Vanhee-Brossollet and Vaquero, 1998; Luther, 2005). 
This regulation can take place either at the transcriptional or translational level and, in 
addition, the maturation, transport or stability of the mRNA can be affected (Vanhee-
Brossollet and Vaquero, 1998). Negative down-regulation has generally been 
suggested, but positive up-regulation by stabilization of the sense transcript is also 
conceivable. 
Two possible mechanisms for antisense mediated regulation have been 
suggested. Due to the similar structure, antisense mRNA may bind to proteins 
interacting with sense mRNA, and thus deprive the sense transcripts from proteins 
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necessary for their expression (Kim et al., 1996; Lehner et al., 2002). Another 
mechanism is analogous to the effects of micro- or short interfering RNAs, where an 
antisense RNA binds to the sense counterpart and forms a duplex. Two plausible 
consequences for this duplex formation have been suggested. The double stranded 
RNAs can either be degraded by double-stranded RNA (dsRNA) specific enzymes 
(Hammond, 2005), or steric hindrance can prevent RNA interacting with molecules 
that are required for expression (Vanhee-Brossollet and Vaquero, 1998). 
 
4.4 Alternative splicing 
As the human genome project produced more sequence and the number of identified 
genes grew, the estimated total number of genes present in the human genome 
declined remarkably. The current estimate of the total number of genes in the human 
genome is only 20 000 to 25 000 (Human Genome Project; http://www.ornl.gov/), not 
significantly more than the estimated 20 000 genes in the worm genome (Hodgkin, 
2001). However, while the estimated total number of genes has been reduced, the 
number of genes known to undergo alternative splicing has expanded. To date, it is 
estimated that 60% of all human genes and 74% of multi-exon genes are alternatively 
spliced (Modrek and Lee, 2002; Johnson et al., 2003). Thus, alternative splicing 
explains how the vast proteomic complexity is achieved with a limited number of 
genes. 
Alternative splice variants can be produced through the use of alternative 
promoters, resulting in differently expressed variants of the same gene (Stamm et al., 
2005). The majority, approximately 75%, of alternative splicing events, however, 
affect the protein coding regions of the genes (Zavolan et al., 2003). New parts can 
either be included or existing parts removed from the protein product. Changes in the 
protein primary structure can affect binding properties, stability or intracellular 
localization of the protein. Post-translational modifications that the protein is subject 
to can also vary. Further, both soluble and membrane bound forms of the same protein 
can be produced through alternative splicing (Stamm et al., 2005).  
A conserved surveillance mechanism, named nonsense-mediated mRNA 
decay (NMD), monitors mRNAs for errors and degrades those containing premature 
termination codons (PTCs) (Hentze and Kulozik, 1999). Several different 
mechanisms by which the NMD machinery operates have been proposed and the 
38  REVIEW OF THE LITERATURE    
current general view involves intron positions as markers for recognition of PTCs and 
cytoplasmic translation as a signal to elicit NMD (Schell et al., 2002). Most pre-
mRNAs undergo processing by capping, splicing and polyadenylation. When splicing 
machinery removes introns, some components of the machinery, namely the exon 
junction complex (EJC), remain at the splice junctions of the mature transcript (Le Hir 
et al., 2000). In one of the proposed mechanisms for NMD during the first round of 
translation ribosomes remove the EJCs, but as the ribosome halts at the translation 
termination codon EJCs downstream of the termination codon are not removed. The 
remaining EJCs recruit Upf proteins which in turn interact with the translation 
termination factors and trigger the NMD process (Thermann et al., 1998; Baker and 
Parker, 2004). Hundreds of human genetic disorders are influenced by this 
mechanism, since about 25% of all known human mutations produce PTCs and are 
predicted to trigger NMD (Culbertson, 1999).  
Recently, alternative splicing has emerged as an important mechanism 
regulating not merely protein diversity, but also protein expression (Lareau et al., 
2004; Stamm et al., 2005). Introduction of PTCs to mRNAs through alternative 
splicing has been shown to be a relatively common feature of the human 
transciptome, with 25% to 35% of alternative exons introducing frameshifts or 
premature stop codons into the pre-mRNA (Stamm et al., 2005). Since PTCs expose 
mRNAs as targets for NMD, alternative splicing provides a mechanism to regulate 
protein expression through unproductive splicing and mRNA surveillance (Lewis et 
al., 2003; Hillman et al., 2004). Further, nonsense surveillance is not only limited to 
premature termination codons, but NMD degrades a variety of aberrant mRNAs by 
recognizing alterations in normal spatial relationships between the termination codon 
and other pre-mRNA features (Baker and Parker, 2004). Lately, a microarray-based 
approach was used to demonstrate that NMD regulates hundreds of physiologic 
human transcripts, and not just those containing nonsense mutations, supporting the 
idea that the predominant role for NMD is to regulate expression levels of a wide 
variety of physiologic mRNAs rather than just modify disease caused by nonsense 
mutations (Mendell et al., 2004; Alonso, 2005). It has been estimated that at least one-
third of all alternatively spliced mRNAs are downregulated by NMD (Maquat, 2005). 
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AIMS OF THE STUDY 
 
 
1. To characterize the TRIM37 gene in detail by characterizing the genomic structure 
of the gene and identifying alternative splice variants and the regulatory promoter 
region  
 
2. To identify and characterize mutations in TRIM37 underlying mulibrey nanism 
 
3. To characterize the mouse Trim37 gene 
 
4. To study the tissue expression of TRIM37 in humans and mice 
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MATERIALS AND METHODS 
 
Thirtyone recently diagnosed mulibrey nanism patients of different ethnic 
backgrounds were included in the mutational analysis of this study. The patients were 
diagnosed by local clinicians, and some of them fulfill the diagnostic criteria of 
mulibrey nanism, while some showed just short stature and some mulibrey-like 
features. Additionally, thirtyfive Finnish patients, with short stature and some 
mulibrey-like features were analysed. All samples were obtained after informed 
consent was received from the patients or their guardians. The control samples were 
from the Centre d’Etude du Polymorphisme Humain (CEPH). Studies including 
patients have been approved by the Ethics Committee for the Department of Medical 
Genetics, University of Helsinki.  
The methods used in the original articles included in this thesis are 
summarized in Table 4.  
 
Table 4. Methods used in this study 
Method Original publication 
Mutation analysis I, II 
Site-directed mutagenesis I, II 
DNA and RNA extraction I, II 
DNA sequencing I, II, III, IV 
Recombinant DNA techniques (cloning) I, II, III 
Gel electrophoresis (PAGE, SSCP) I, III 
Primer extension III 
Quantitative real-time PCR III 
Cell culture I, II, III 
Transient transfections I, II, III 
Immunofluorescence staining I, II 
Immunofluorescence microscopy I, II 
Northern blot analysis III, IV 
Southern blot analysis I 
Western blot analysis I, II 
Luciferase-reporter assays III 
Immunohistochemistry IV 
Production of GST-fusion proteins II 
Immunoprecipitation II 
In vitro ubiquitination assays  II 
Database and computer analysis I, II, III, IV 
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RESULTS AND DISCUSSION 
 
1. Characterization of the TRIM37 gene (I, III, unpublished) 
1.1 Genomic structure (I, III, unpublished) 
Before this study the TRIM37 gene had been identified as the causative gene 
underlying mulibrey nanism. However, at that time only a 4111-bp cDNA sequence 
(KIAA00898) was available, and this study begun by determination of the complete 
genomic structure of TRIM37. At that time the human genome project was ongoing 
and a vast amount of genomic sequence had already been produced and was readily 
available in public databases. However, the sequence was not complete and many 
gaps existed. A search through the public databases revealed two genomic sequences 
covering the 5´ (nts -273-684; exons 1-8) and 3´ (nts 810-4111; exons 10-24) ends of 
the TRIM37 gene. No genomic sequence was available for a 125-bp part of the cDNA 
sequence (nts 685-809; exon 9) at that time. The database genomic sequences were 
organized according to the cDNA sequence. To fill the remaining gap, PCR-amplified 
products between the flanking genomic sequences and the cDNA sequence between 
them were sequenced. This enabled us to assemble a single genomic sequence 
covering the whole TRIM37 genomic region, including nts 685-809, with only minor 
intronic gaps. Later, when the human genome project produced more sequence, the 
genomic sequence we assembled was confirmed and completed with a novel 
chromosome 17 genomic sequence contig (NT_010783).  
By aligning the cDNA sequence to the assembled genomic sequence, we 
determined the genomic size of TRIM37 to be approximately 109 kb. The TRIM37 
gene was initially found to have 24 exons. Later an additional 25th exon was found 
and the full genomic size was extended to approximately 125 kb. The sizes of the 
exons range from 41 to 309 bp, and the introns from 1.2 to 16.5 kb. All the splice 
junctions follow the conserved GT-AG rule. The sequences of the exon-intron 
boundaries and the sizes of all the exons and introns are shown in Table 5. A 
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Table 5. TRIM37 exon-intron boundaries.  
The coding exonic sequences are shown in capital letters while the non-coding intronic 









1 294 (21)  GAGCGTGGAGgtgagggggt 1 2.0 
2 102 ctgttttcagAGCATTGCTG CTGTATTAGGgtaagttgta 2 13.0 
3 41 gcccccttagCGCTGGCTGA CTCATTGCCGgtaagtgttt 3 2.9 
4 117 ttctccccagTGCTCCACTC AAAAGGACAAgtatgtcctc 4 4.2 
5 88 taatgtatagATGTGAAAAT GGGAGGAATGgtgagcagaa 5 2.8 
6 123 atttaaatagCATGGCGGAC TCAAGAAGTGgtaagactac 6 1.2 
7 124 tatcttctagGAAAGGAATG ACACTGATGGgtaagtgttt 7 4.0 
8 68 ttttcatcagGTCAGAAGAC GGAGCACCAGgtgatgaaat 8 5.1 
9 125 cctcacacagTTGCGGTCTT ACTTTACCAGgtatgacaca 9 6.6 
10 51 ttttttttagTGAATTAGTG AGAATTTCAGgtaagagttt 10 1.7 
11 82 ttttcgttagCACTTTGCGT AGTTTACCCAgtaagttttt 11 1.5 
12 77 cttcttttagGATGGAAATG AAACTTCTAAgtaagaagtg 12 4.0 
13 180 tcaattttagATATGAATAT TGATTTTAAGgtaacaggaa 13 5.5 
14 115 ttcttttaagGTTTCAGGTA CCTTAAAGAGgtaagaaaat 14 1.8 
15 216 gttttaaaagAGACTTACTA AGATTATCATgtaataatga 15 1.4 
16 137 attgatctagCACGAGCTTT AAGAAACTATgtgagtttcc 16 5.8 
17 86 atattcttagGTCTGGAGAA GGACCCGCAGgtaatgaggt 17 9.7 
18 195 tcttttgcagGTAGTAGCCA CAGCCCACAGgtaaaataat 18 3.2 
19 309 ttctctgaagCATCATATTC ATACGAAACTgtaagtaata 19 11.0 
20 129 gtctttgcagCCACAAATAA CTGTCTGAAGgtaaatttga 20 1.5 
21 190 ttttttgaagGCTCCCCAGG TCACCTTGGGgtaaattaag 21 3.2 
22 119 cttctttgagGGCTAATGCT CCTGAAGAAGgtaaggaatg 22 10.6 
23 117 ttcctgccagGAATGAGTAG CCGGATGAAGgtgcagcaca 23 2.1 
24 79/>1254 ttaatcatagATACACATTC ATAGTGGAAGgtaattgcca  24 16.5 
25 >284 gttttcttagATAATTTGAT    
*The coding region of exon 1 is shown in parentheses and two different forms of exon 24 are presented 
representing the alternative splice forms of this exon. Exon 25 is present only in the splice form with 
the shorter exon 24 (see section 1.2.1).  
 
1.2 Alternative splicing (III) 
Northern analysis of the TRIM37 gene shows a 4.5-kb transcript present in all tissues 
studied, and an additional 3.6-kb transcript in testis (Avela et al., 2000). Further, 
amplification of the TRIM37 coding region by RT-PCR resulted in several alternative 
products of different lengths. To identify alternative splice variants of TRIM37, with 
special emphasis on the shorter transcript seen in testis, a BLAST search was run of 
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the human EST database. The search returned 211 sequences derived from several 
different tissues. Among these EST sequences, 12 alternatively spliced forms of 
TRIM37 were found (Table 6). RT-PCR experiments confirmed these alternative 
sequences and revealed 18 additional variants (Table 7). Most of these 30 alternative 
variants predict non-functional protein products, 13 by deleting functional domains 
and 11 by producing premature termination codons (PTCs), while two predict in-
frame insertion of 9 or 16 aas into the polypeptide.  
 
Table 6. Alternative splice variants of TRIM37 identified from the EST sequences and 
confirmed with RT-PCR. 
EST clone(s), tissue Difference to NM_015294 Predicted protein product 
BC036012, AW589999, testis Trim37b# 964 aa identical to TRIM37 
AK025648, hepatoma Trim37a, del exon 23  925 aa TRIM and TRAF intact 
BM979745, lung Trim37b, del exon 23 925 aa TRIM and TRAF intact 
AI307801, kidney Trim37b, exon 23 ins27 973 aa TRIM and TRAF intact 
BE703384, brain additional exon 8B (48 nt) 980 aa TRIM and TRAF intact 
AA460052, AA460884, total fetal exons 1-10 + intron 10 287 aa TRAF domain missing 
BI913823, brain exons 1-4 + intron 4 121 aa only RING domain left 
BG721833, testis del exon 2 930 aa RING domain missing 
BG997038, head/neck del exon 5 113 aa PTC* 
BG220351, fibrosarcoma del exon 8 209 aa PTC 
BX537955, testis additional exon 3B (76 nt) 67 aa PTC 
BI831450, brain additional exon 3B + intron 4 67 aa PTC 
# See section 1.2.1 for details of TRIM37b 
* PTC = premature termination codon 
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Table 7. Alternative splice variants of TRIM37 identified by RT-PCR. 
mRNA template tissue Difference to NM_015294 Predicted protein product 
testis del exons 5-12 718 aa only RING domain left 
testis del exons 5-13 658 aa only RING domain left 
lymphoblast del exons 5-15 and part of exons 4 and 
16 (c.273_1649) 
505 aa only RING domain left 
heart del exons 5-17 and part of exon 4  
(c.271_1758) 
468 aa only RING domain left 
testis del exons 4-16 463 aa only RING domain left 
testis del exons 14-23 and part of exon 13 
(c.1062_2810) 
381 aa TRIM and TRAF intact 
testis del exons 3-17 and part of exons 2 and 
18 (c.57_1892) 
352 aa TRIM and TRAF missing 
heart del exons 10-22 and part of exons 9 and 
23 (c.808_2718) 
327 aa, TRAF domain missing 
heart del exons 12-21 317 aa PTC 
placenta del exons 11-23 293 aa TRAF domain missing 
testis del exons 10-23 276 aa TRAF domain missing 
placenta del exons 5, 8-13, 15-16, 18-19, 21, and 
23  
113 aa PTC 
placenta del exons 5-18 and part of exons 4 and 
19 (c.262_2075) 
111 aa PTC 
testis del exons 5-23 100 aa only RING domain left 
heart, testis, placenta, 
lymphoblast 
del exons 5-19 96 aa PTC 
testis del exons 9-23, additional exon 2B (188 
nt c.123+102_123+289) 
68 aa PTC 
testis del exons 3-19, ins part of intron 22 
(c.2696-41_2691-1) 
56 aa PTC 
testis del exons 4-22 and part of exons 3 and 
23 (c.157_2714) 
53 aa PTC 
 
 
Both in silico analyses and RT-PCR experiments showed that alternative splicing of 
TRIM37 is relatively frequent. However, most of the alternative TRIM37 transcripts 
seem to be expressed transiently and at fairly low levels. They are not seen in other 
species and RT-PCR favors the major transcripts over them. Further, many of them 
predict either non-functional or truncated protein products. The relatively frequent 
occurrence of seemingly non-functional splice variants suggests that alternative 
splicing has a role in regulating TRIM37 expression post-transcriptionally through 
regulated unproductive splicing and translation and nonsense surveillance (Lewis et 
al., 2003). The TRIM37 gene is fairly large (~125 kb), thus the transcription is time 
consuming and if rapid changes on the protein level are needed, translational 
regulation of expression has much more prompt effects than transcriptional 
regulation. A similar phenomenon is seen for example for TRIM18 (also known as 
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MID1) underlying OS, where alternative splicing is thought to regulate MID1 
function translationally by producing variants that predict loss-of-function via 
introduction of PTCs or altered interaction properties of the splice isoforms. This is 
further thought to underlie the tissue specific function of MID1 and the fact that the 
clinical features of OS are confined to the developing ventral midline, while MID1 
mRNA is ubiquitously expressed (Winter et al., 2004). 
Only four of the alternative TRIM37 transcripts seem to be expressed 
constantly (Figure 5). TRIM37a, the database transcript, TRIM37b, a testis specific 
variant encoding a protein product identical to TRIM37a (see next section 1.2.1 for 
details), and in addition both of these two major transcripts have variants that lack 
exon 23. The skipping of exon 23 predicts an in-frame deletion of 39 amino acids, 
including an evolutionarily conserved DES (aspartate-glutamate-serine)-rich motif 
near the C-terminus (Figure 6). Whether the DES-rich region has any functional 
relevance is not known, and thus the physiological function of this transcript or 
whether it has any functional role is unknown. However, the transcripts lacking exon 





Figure 5. The four major alternative splice variants of TRIM37.  
Structure of the 3' ends of the four constantly expressed TRIM37 transcripts. The genomic 
structure of the TRIM37 gene downstream of exon 22 is shown in the middle. The TRIM37a 
and TRIM37b transcripts encode identical protein products but use different termination 
codons and have different 3’ untranslated sequences. In the TRIM37a transcript the whole 
exon 24 sequence is included whereas in the TRIM37b transcript, only the first 79 nucleotides 
of exon 24 are included followed by an additional exon (exon 25), predicting a shorter 
transcript (~3.6 kb). Both a and b forms have additional variants where exon 23 is deleted. 
Coding regions are shown in grey and untranslated regions in white.  
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Figure 6. Alignment of the C-terminal parts of human, dog, mouse, chicken and 
zebrafish Trim37 proteins. The 39 amino acid region containing the DES-rich region 
deleted in the transcript that lacks exon 23 is boxed. 
 
When transiently over-expressed, the TRIM37adel23 protein showed vesicular 
staining compatible with the peroxisomal localization of the full length protein, 
implicating that the 39 amino acid deletion does not result in altered subcellular 
localization. This is in line with previous studies showing that the coiled-coil region is 
responsible for subcellular localization in TRIM proteins (Reymond et al., 2001). 
Expression levels of TRIM37a and TRIM37b were further studied with 
quantitative real-time PCR. As expected from the northern analysis, expression of 
TRIM37 was seen in all tissues studied, with highest expression in testis, where both 
transcripts showed equal expression. High expression of TRIM37a was also seen in 
brain (both fetal and adult), whereas TRIM37b was detected mainly in testis. Brain 
and testis were the most abundant tissue sources also among the database TRIM37 
sequences, with 32 clones from brain and 19 clones from testis. In most of the tissues 
analysed, fetal tissues showed slightly higher expression levels than adult tissues. 
 
1.2.1 TRIM37b (III) 
Among the alternative splice variants predicting functional protein products was a 
testis-specific transcript, which we named TRIM37b. This transcript has an additional 
25th exon, 16 kb downstream of exon 24 (Figure 5). In exon 24 a conserved splice 
donor site precedes the termination codon (TAA), with the intronic GT-sequence of 
the splice donor partly overlapping the termination codon (GTAA). However, in most 
cases this splice junction is not used. In testis, this donor site is activated, which in 
turn activates a novel splice acceptor site 16 kb downstream, and the product of this 
splicing event is TRIM37b. A conserved AG consensus sequence is present at the 
splice acceptor site in exon 25, where nucleotides two to four encode a termination 
codon substituting the exon 24 termination codon of TRIM37a at the identical 
position. Thus, these two transcripts predict identical protein products.  
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Among the identified TRIM37 variants, TRIM37a and TRIM37b were the only 
transcripts with homologous variants seen also in other species (mouse and rat), 
implicating functional relevance for these isoforms. 
The TRIM37b transcript was further shown to correspond to the 3.6-kb testis-
specific fragment seen in northern analysis using 3’ sequence specific probes. 
Hybridization of northern blots with several different probes from the coding region 
detected both the 4.5- and the 3.6-kb transcripts (publication III; Figure 4). On the 
contrary, hybridization with a TRIM37a 3’ UTR probe (c.2920-3499) detected only 
the 4.5-kb transcript. Hybridization with a TRIM37b exon 25 probe resulted in several 
differently sized transcripts including the 3.6-kb TRIM37 transcript. The other 
transcripts seen with this probe were identified as representing PPM1E 
(NM_014906). The PPM1E gene resides on the complementary strand and has 3’ 
UTR sequence that overlaps with exon 25 of TRIM37. It encodes a protein 
phosphatase 1E, a protein belonging to the PP2C family of Ser/Thr protein 
phosphatases that act as negative regulators of cell stress response pathways. PPM1E 
inhibits actin stress fiber breakdown and morphological changes driven by cell 
division cycle 42 (CDC42) (Koh et al., 2002).  
The 3’ UTR sequence has several functions in regulating gene expression. It 
can affect mRNA stability, localization of the mRNA molecules in a cell, and 
provides the basis for translational control by harboring specific regulatory sequences 
that bind regulatory proteins (Wickens et al., 1997). Thus, the function of transcripts 
with alternative 3' UTRs coding for identical protein products is most likely 
regulatory. The presence of TRIM37 transcripts with alternative 3’ sequences 
specifically in testis implies that TRIM37 expression is strictly regulated there. A 
similar phenomenon is seen for RNF4, another RING finger protein that has a 
translationally repressed testis specific transcript (Pero et al., 2003). The PPM1E gene 
on the complementary strand may also provide a mechanism through which TRIM37 
expression is regulated in testis. Transcribed from the opposite strands, TRIM37b and 
PPM1E could act as cis-encoded antisense transcripts and downregulate each other's 
expression.  
Immunohistochemical studies on mouse tissues showed that Trim37 
expression in testis is limited to developing spermatids (see section 4, Figure 11) and 
strict regulation of gene expression is known to be extremely important in germ cells 
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(Braun, 1998; Eddy and O'Brien, 1998). Thus, as mulibrey nanism patients are 
subfertile (Lipsanen-Nyman, 1986; Karlberg et al., 2004b), this may well be 
specifically due to TRIM37 dysfunction in developing germ cells.  
 
1.3 Transcription initiation and promoter region (III) 
To identify the transcription initiation site for TRIM37, a primer extension assay was 
performed. Several products corresponding to transcription start sites within a 
window of approximately 130 nts between nts -373 to -246 upstream of the ATG 
codon of the translation initiation site were produced.  
To identify the promoter region of TRIM37, 5’ flanking sequences of human, 
mouse and rat genes were aligned and run through different promoter prediction 
programs. The in silico analysis predicted an active promoter region starting from the 
translation initiation site and continuing 600 nucleotides upstream. This putative 
promoter sequence showed high homology to mouse (71%) and rat (72%) 5’ flanking 
sequences. Several transcription factor-binding sites in this region were predicted to 
be present in all three species.  
To assess whether the putative promoter region has promoter activity, different 
segments of the region were cloned in front of a promoterless luciferase reporter gene. 
All reporter constructs showed approximately 400 times the activity of the empty 
pGL3-basic vector, indicating that the elements essential for promoter activity are 
present in the shortest segment (nt -591 to -246). As the construct with the longest 5’ 
sequence in inverse orientation showed only one fourth of the activity of the construct 
with the same sequence in forward orientation, the promoter activity seems to be 
orientation dependent. 
Thus, the functional analyses confirmed the in silico prediction of a 600-bp 
promoter and showed that nucleotides -591 to -246 relative to the translation initiation 
site harbor the elements sufficient for strong basal activity. This promoter region is 
G+C rich (70%) and TATA-less, showing features typical of a house-keeping gene. 
However, as the protein expression shows a strictly regulated cell-specific pattern, 
this further suggests a role for translational regulation in controlling TRIM37 
expression. The TATA-box plays a critical role in determining the site for 
transcription initiation and several examples exist of TATA-less promoters that lack a 
unique transcription start site. Instead, these TATA-less promoters have multiple, 
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sometimes widely dispersed sites of transcription initiation (Reynolds et al., 1985; 
Geng and Johnson, 1993). This seems to be true also for TRIM37, where several 
transcription initiation sites are dispersed in a window of 130 nts. 
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2. Identification of mulibrey nanism associated mutations (I, II, 
unpublished) 
Characterization of the genomic structure of TRIM37 allowed mutation screening for 
patients for whom no RNA was available. We amplified and sequenced all exons and 
the putative 600 bp promoter region with flanking intronic primers and consequently 
detected fourteen novel changes in eleven patients, two of these present in the same 
disease chromosome (Table 8).  
 
Table 8. Mutations of the eleven mulibrey nanism patients included in this study 
Origin of patient Mutations Reference 
Canadian  p.[Gln249X]+[ Met347fs] I  
Canadian p.[Gly322Val]+[Arg471X] I 
Tunisian p.[Arg471X]+[Arg471X] I 
Sicilian p.[Arg439fs]+[Arg439fs] I 
Saudi-Arabian p.[Arg686X]+[Arg686X] I 
Australian p.[Cys109Ser]+[Glu271_Ser287del] II 
French p.[Cys28fs]+[Cys28fs] unpublished 
German p.[Lys411fs ]+[Lys411fs] unpublished 
Swiss-Finnish* p.[Arg166fs]+[Gln638fs]  unpublished 
Turkish p.[Glu632fs;Ala133Val]+[Glu632fs;Ala133Val] unpublished 
Finnish* p.[Arg166fs]+[Tyr389X] unpublished 
*These two patients were compound heterozygotes for a novel mutation and the Finnish 
major mutation (p.Arg166fs) identified by Avela et al. 2000. 
 
Like the previously identified mutations in TRIM37, most of the new mutations 
predict premature termination codons. Four of the new mutations were transitions, 
c.745C>T, c.1166A>G, c.1411C>T and c.2056C>T, leading to nonsense mutations 
and premature stop codons p.Gln249X, p.Tyr389X, p.Arg471X and p.Arg686X,  
respectively, and thus predicting either truncation of the protein products or mRNA 
degradation through NMD.  
Five novel changes were small insertions or deletions. Two were one 
nucleotide deletions (c.81delG and c.1233delA) resulting in frame-shifts (p.Cys28fs 
and p.Lys411fs, respectively) and PTCs. In one patient a 2-nt deletion 
(c.1894_1895delGA) was detected, and a 2-nt duplication (c.1910_1911dupTA) was 
observed in another patient. These two also lead to frame-shifts and PTCs (p.Glu632fs 
and p.Gln638fs, respectively). In addition, a 4-nt duplication 
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(c.1037_1040dupAGAT), also leading to a frame-shift (p.Met347fs) and PTC, was 
detected in one patient.   
In one patient, no PCR products were amplified from exons 15 and 16, while 
other exons amplified normally. A long-range PCR from exon 14 to 17 produced a 
900-bp product, while the genomic distance between these exons is over 9 kb. 
Sequencing of this PCR product revealed a genomic deletion of 8603 bp 
(IVS14+506_IVS16-206del). This genomic deletion was also detected in Southern 
analysis using several different restriction enzymes. On the protein level this mutation 
leads to a frame-shift (p.Arg439fs) and PTC. The deletion breakpoints in introns 14 
and 16 are embedded within identical AluY repeat sequences, suggesting Alu-
mediated homologous recombination as a deletion mechanism.  
In addition to the above ten mutations producing PTCs, two single nucleotide 
substitutions, c.326G>C and c.965G>T, resulting in missense mutations in exons 5 
and 12 (p.Cys109Ser and p.Gly322Val) were seen in the patients (see section 2.1 for 
further results and discussion). Both of these amino acids, the cysteine at position 109 
and the glycine at position 322, are evolutionarily conserved down to zebrafish. 
Additionally, a homozygous missense change (c.398C>T; p.Ala133Val) was 
seen in a Turkish patient homozygous for the p.Glu632fs mutation. This change was 
seen in heterozygous form in the parents of the patient, and was not present in the 
healthy brother of the patient (who did not carry the p.Glu632fs mutation), indicating 
that both changes reside in the same chromosome in both parents. This change was 
not seen in 100 Turkish control chromosomes, nor was it present in 100 CEPH control 
chromosomes. Further, the alanine at position 133 is evolutionarily conserved. 
However, when analysed with the PolyPhen program (Polymorphism Phenotyping; 
http://genetics.bwh.harvard.edu/pph), the p.Cys109Ser and p.Gly322Val mutations 
are predicted to be damaging while the p.Ala133Val change is predicted to be benign. 
Whether this is a pathogenic mutation or a rare normal polymorphic variant cannot be 
determined with the present data. However, the p.Glu632fs change is most likely the 
disease associated change in this family since it is likely to trigger NMD and lead to 
degradation of mRNA. Thus no p.Ala133Val mutant protein is likely to be produced.  
The fourteenth change we detected was a splice site mutation (c.860G>A), 
affecting the 5’ splice acceptor site of exon 10. In mRNA this results in skipping of 
52  RESULTS AND DISCUSSION    
exon 10 and leads to an in-frame deletion of 17 amino-acids from the TRAF domain 
(p.Glu271_Ser287del). 
Altogether 190 CEPH control alleles were analysed for each novel mutation. 
While the p.Gln638fs mutation was observed in heterozygous form in one control 
individual, the other mutations were not seen among the control alleles.  
In some patients, no mutations were found in the exonic sequences, flanking 
intronic sequences or in the putative 600-bp promoter region. We looked for large 
genomic rearrangements using Southern analysis, but no differences were detected 
between these patients and controls. As no RNA was available from these patients, 
mutations in introns or regulatory regions affecting splicing or the transcript levels 
may well have remained undetected. Moreover, even though the 8.6-kb genomic 
deletion seen in homozygous form in one patient was detectable in Southern analysis, 
small genomic rearrangements, especially if in heterozygous form, may have been 
undetected. The existence of such rearrangements are likely, due to the high number 
of Alu-repeat sequences in introns of TRIM37 (approximately one repeat every kb), as 
other genes with high numbers of Alu repeats have high frequencies of pathogenic 
deletions involving Alu repeats (Rüdiger et al., 1991; Bertolini et al., 1992). 
Additionally, the possibility of genetic locus heterogeneity in mulibrey nanism cannot 
be ruled out.  
With six mutations reported previously (Avela et al., 2000; Jagiello et al., 
2003; Kallijärvi et al., 2005), the total number of mulibrey nanism-associated 
mutations in TRIM37 is now 19 (Table 9). The p.Ala133Val change is not included in 
this number, as it may be a rare polymorphism with no effect on TRIM37 function. 
No mutational hotspots are seen and the 19 TRIM37 mutations are distributed evenly 
from exon 2 to exon 19 (Figure 7). Apart from the Finnish founder TRIM37 mutation, 
accounting for 98% of disease associated chromosomes in Finnish patients (Avela et 
al., 2000), all other mulibrey nanism-associated mutations were observed in only one 
or two families. 
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Table 9. Mutations in TRIM37 associated with mulibrey nanism. 
The FinMajor mutation, present in 98% of Finnish disease associated chromosomes and all 
Finnish patients, is shown in bold. All other mutations are seen in only one or two families. 





c.81delG deletion 2 p.Cys28fs; NMD unpublished 
c.227T>C missense 4 p.Leu76Pro Kallijärvi et al. 2005 
c.326G>C missense 5 p.Cys109Ser II 
c.493-2A>G splice-site 7 p.Arg166fs; NMD Avela et al. 2000 
c.745C>T nonsense 9 p.Gln249X; NMD I 
c.810-1G>A splice-site 10 p.Glu271fs; NMD Jagiello et al. 2003 
c.838_842delACTTT deletion 10 p.Thr280fs; NMD Avela et al. 2000 
c.860G>A splice-site 10 p. Glu271_Ser287del II 
c.965G>T missense 12 p.Gly322Val I 
c.1037_1040dupAGAT duplication 13 p.Met347fs; NMD I 
c.1166A>G nonsense 13 p.Tyr389X; NMD unpublished 
c.1233delA deletion 14 p.Lys411fs; NMD unpublished 
c.1313+507_1668-207del large deletion 15,16 p.Arg439fs; NMD I 
c.1346dupA duplication 15 p.Ser450fs; NMD Avela et al. 2000 
c.1411C>T nonsense 15 p.Arg471X; NMD I 
c.1894_1895delGA deletion 18 p.Glu632fs; NMD unpublished 
c.1910_1911dupTA duplication 18 p.Gln638fs; NMD unpublished 
c.2056C>T nonsense 19 p.Arg686X; NMD I 




Figure 7. Schematic representation of the TRIM37 gene and protein showing the 
positions of the 19 mutations reported to date in mulibrey nanism patients.  
In the gene picture the coding regions are in dark grey and untranslated regions in light grey. 
The regions that are alternatively present in the major alternative splice variants are striped. In 
the protein picture mutations described in this study are in black and mutations reported 
previously in grey letters.  
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Fifteen of the 19 TRIM37 mutations result in PTCs predicting truncated protein 
products, or presumably destining the mRNAs to degradation by NMD (Mendell and 
Dietz, 2001). TRIM37 mRNA expression in lymphoblastoid cells of Finnish patients 
with the Finnish major mutation was studied by quantitative PCR and only one third 
of the expression of control individuals was detected. This suggests that at least the 
Finnish major mutation leads to down-regulation of TRIM37 mRNA. 
 
2.1 Functional studies of the mutations predicting protein products (I, II) 
Since most of the TRIM37 mutations underlying mulibrey nanism predict PTCs and 
presumably do not produce protein, the functional consequences of the two missense 
mutations (p.Cys109Ser, p.Gly322Val) and the p.Glu271_Ser287del mutation were 
studied further. The cysteine to serine change at position 109 resides in the B-box of 
the TRIM domain (Figure 7). It affects a conserved cysteine residue in a flexible loop 
region of the B-box (Borden et al., 1995) and may interfere with the zinc binding 
properties of the B-box.  The glycine to valine substitution at position 322 is located 
in the TRAF domain of TRIM37 (Figure 7). Glycine is the smallest amino acid and is 
often located in critical positions for correct protein folding. The substitution of 
glycine with the bulkier valine may thus result in misfolding of the protein. The 
skipping of exon 10 due to the splice site mutation leads to deletion of the 17 first 
amino acids from the TRAF domain (Figure 7).  
 
2.1.1 Subcellular localizations of the mutant proteins (I, II) 
The subcellular localizations of the p.Cys109Ser, p.Gly322Val and 
p.Glu271_Ser287del mutant proteins were studied in transiently transfected BHK and 
COS-1 cells. In contrast to the granular pattern seen with the wild-type TRIM37 
(Kallijärvi et al., 2002), the mutant proteins showed homogenous cellular staining, 
indicating that the mutant proteins lose the peroxisomal localization (Figure 8). None 
of the mutant proteins formed aggresomes, which have previously been reported for 
the ectopically expressed wild type TRIM37 (Kallijärvi et al., 2005).  
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Figure 8. Subcellular localizations of the wild-type and mutant TRIM37 proteins.  
COS-1 cells transiently transfected with HA-tagged wild-type or mutant TRIM37 and 
analysed by anti-HA antibody. While the wild type TRIM37 shows granular cytoplasmic 
localization all three mutant proteins show homogeneous cytoplasmic staining, indicating loss 
of peroxisomal localization. 
 
 
Two of these mutations affect the TRAF domain and one the B-box domain of 
TRIM37, thus the cytoplasmic localizations were somewhat surprising since the 
coiled-coil region, which has previously been considered to be necessary and 
sufficient for proper subcellular targeting of TRIM family proteins (Reymond et al., 
2001), is intact in all these mutant proteins. Thus our data suggests that even though 
the coiled-coil region is necessary for the proper subcellular localization of TRIM37 it 
is not sufficient in itself, as the B-box and TRAF domains also play roles in targeting 
TRIM37 in the cell. However, since TRIM37 has no peroxisomal targeting signals, 
the localization is most likely dependent on interaction with another, yet unidentified, 
protein and both the TRAF and the B-box domains have been implicated to have a 
role in interactions (Borden, 1998; Zapata et al., 2001). Thus, the mutations may 
interfere with TRIM37 interaction with the protein responsible for the peroxisomal 
localization. Whether the mutations directly affect the interacting domains of TRIM37 
or merely change the overall folding of the protein and thus indirectly affect the 
interaction properties of TRIM37 is not known. Whatever the mechanism by which 
the mutant proteins lose the peroxisomal localization, the false subcellular localization 
suggests non-functionality of these mutant proteins. It also implies that peroxisomal 
localization is vital for the proper function of TRIM37. 
 
2.1.2 Ubiquitin ligase activities of the mutant proteins (II) 
As TRIM37 has been shown to possess ubiquitin E3 ligase activity, and a p.Leu76Pro 
mutation in the TRIM domain has been shown to result in diminished 
autoubiquitination of the mutant TRIM37 (Kallijärvi et al., 2005), the effect of the 
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p.Cys109Ser B-box mutation affecting the TRIM domain on the ligase activity was 
studied in cultured cells by studying autoubiquitination of the mutant protein. 
Expression constructs of full-length TRIM37 or its TRIM domain and hexahistidine-
ubiquitin expression plasmid were co-transfected into COS-1 cells and 
immunoprecipitated by aminoterminal HA-tag to enrich the proteins. The 
immunoprecipitates were analysed by immunoblotting with either anti-ubiquitin or 
anti-HA antibodies. A high molecular mass ubiquitin positive smear, similar to the 
one seen with the wild type protein, was seen for the mutant protein suggesting that it 
has retained its E3 ligase activity (Publication II; Figure 3a). Similar results were 
achieved in in vitro ubiquitination assays, where GST-TRIM fusion proteins were 
incubated with ubiquitin in rabbit reticulocyte lysates (Publication II; Figure 3b). 
These results of a B-box mutation not affecting the ubiquitin ligase activity of 
TRIM37 are in line with previous studies where the RING finger has been shown to 
be essential for ubiquitin E3 ligase activity in RING proteins in general as well as in 
TRIM37 (Pickart, 2001a; Kallijärvi et al., 2005).  
The two other new mutations, p.Gly322Val and p.Glu271_Ser287del, affect 
the TRAF domain of TRIM37 and thus are not likely to affect the E3 ligase activity. 
However, the autoubiquitination properties of the p.Glu271_Ser287del mutation were 
analysed in co-immunoprecipitation experiments with ubiquitin and the mutant 
TRIM37 protein. As expected, no difference could be detected between the wild-type 
TRIM37 and the deletion mutant. Further, the E3 ligase activity of the p.Gly322Val 
mutant protein has been studied outside of this study and similar autoubiquitination 
activity to wild-type TRIM37 has been detected for the mutant protein (Kallijärvi et 
al., 2005). Thus, none of these three mutations seem to affect the ubiquitin ligase 
activity of TRIM37. 
 
2.1.3 Interaction properties of the p.Cys109Ser mutant (unpublished)  
The B-box motif has been reported to participate in interactions of TRIM proteins 
(Borden, 1998). For example, a B-box missense mutation in TRIM18 that underlies 
OS has been shown to reduce the affinity of the B-box to its interaction partner α4, 
and thus lead to OS (Schweiger and Schneider, 2003), suggesting that B-boxes are 
critical for the correct interaction properties of TRIM proteins. Thus, as the loss of 
ubiquitin E3 ligase activity is not responsible for the loss-of-function of p.Cys109Ser 
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mutant TRIM37, the interaction properties of the mutant protein were studied. GST-
fusion proteins of the mutant and wild-type TRIM37 were produced, and their binding 
to three putative interaction partners, SULT1A2 (sulfotransferase 1A2), NICE-3 and 
prohibitin, identified in yeast-two-hybrid screens (Kallijärvi, 2006), were studied with 
GST pull-down assays. The mutant protein bound all three putative interaction 
proteins, but the binding was weaker than that seen with the wild type protein (Figure 
8), implying that the mutation interferes with the interaction properties of TRIM37. 
These data are very preliminary and whether the putative interaction partners also 
bind TRIM37 in vivo is unknown.  
Impaired interaction properties may also underlie the pathogenesis of the 
p.Gly322Val and p.Glu271_Ser287del mutations, as they affect the TRAF domain 
and TRIM37 has been shown to bind to other TRAF proteins and itself via the TRAF 
domain (Zapata et al., 2001).  
 
 
Figure 9. GST- pull down assays of the TRIM domain of TRIM37 and its putative 
interaction partners. 
Putative interaction partners of TRIM37 were translated in vitro and the reaction products 
were incubated with either wild type or p.Cys109Ser mutant TRIM-GST fusion protein 
coupled to glutathione-sepharose beads. The bound proteins were analysed by 
immunoblotting with an anti-HA antibody. The mutant protein binds all three interaction 
partners, but the binding is weaker than for the wild type protein (upper panel). Green 
fluorescence protein (GFP) was used as a negative control that does not interact with TRIM. 
All in vitro translated proteins were detected in approximately equal amounts in the first wash 
after pull down (middle panel) and the GST-TRIM fusion protein was detected in 
approximately equal amounts with anti-GST antibody (lower panel). 
 
2.2 Genotype-phenotype correlation 
In recessive disorders the disease is usually due to the loss of functional protein and 
all changes causing loss-of-function result in a similar phenotype. In dominant 
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disorders, however, mutations often cause gain-of-function, i.e. the mutated protein 
gains an abnormal function, and thus different mutations may result in differences in 
phenotypes or even completely different diseases.  
The 19 TRIM37 mutations identified to date all seem to produce loss-of-
function alleles, and consequently no genotype-phenotype correlation is seen in 
mulibrey nanism patients. However, the phenotypic picture of mulibrey nanism 
patients is variable. The overall appearance is very similar between patients but 
several different features can be seen, only some of them present in all patients, and 
while some patients can live a nearly normal life others have severe health problems. 
This variability is also seen among the Finnish patients homozygous for the Finnish 
founder mutation (Perheentupa et al., 1970; Perheentupa et al., 1973; Karlberg et al., 
2004a), implying that the variability is not directly due to the TRIM37 dysfunction 
but rather to other modifying genetic or environmental factors. All patients show the 
key clinical characteristics of prenatal-onset growth failure, dysmorphic craniofacial 
features, J-shaped sella turcica, hepatomegaly and moderate or severe signs of 
mulibrey heart disease (Perheentupa et al., 1970; Perheentupa et al., 1973; Karlberg et 
al., 2004a). Other organ manifestations such as hypothyroidism, hypoplasia of 
endocrine organs, ovarian fibrothecomas, liver tumors and Wilms’ tumors are 
variably present in some patients. Thus, it looks like TRIM37 mutations cause a 
variable, yet distinct clinical phenotype with the variance in the phenotype being 
caused by modifying genetic or environmental factors. 
The clinical picture of mulibrey nanism resembles other growth disorders, and 
as it is extremely rare outside of Finland, most clinicians may have never encountered 
a mulibrey nanism patient. Thus, several mulibrey nanism patients without a proper 
diagnosis may exist around the world. Also, as we could not detect mutations in all 
the patients studied, a probable reason for this is that they may not suffer from 
mulibrey nanism but instead have some other growth restriction syndrome with 
similar features. During this study approximately 30 Finnish and 15 non-Finnish 
patients with short stature and some mulibrey-like features, but not a phenotype 
fulfilling the diagnostic criteria formed on the basis of clinically relatively uniform 
Finnish patients molecularly confirmed to have TRIM37 mutations, were screened for 
TRIM37 mutations, but no changes were detected in them.  
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3. Mouse Trim37 (IV, unpublished) 
3.1 Comparative genomics 
Comparison of the Trim37 genes from different species revealed high evolutionary 
conservation among all vertebrates, whereas the Trim37 gene is not seen in the 
genomes of lower species. In all vertebrates studied (human, chimp, mouse, rat, 
zebrafish) the cDNA sequences showed high homology and the genomic structures of 
the orthologs were identical with exon-intron junctions at identical positions.   
Comparison of Trim37 proteins reveals even higher evolutionary conservation 
and homology than that seen on the gene level. Especially the N-terminal part of the 
protein that includes the TRIM domain as well as most of the TRAF domain (aa 1-
385) is highly conserved. The N-terminal part of human TRIM37 shows 100% 
identity with other mammalian, 99% identity to the chicken and 96% identity to the 
zebrafish Trim37 proteins. Though the C-terminal part of the protein is much less 
conserved than the N-terminus, high conservation is seen for the whole protein, with 
the mouse Trim37 showing 92% identity to the human protein.  
Figure 10 shows alignment of human, mouse, chicken and zebrafish Trim37 
proteins. 
 
3.2 Characterization of the mouse Trim37 gene (IV) 
The pathogenetic mechanisms behind a developmental disorder like mulibrey nanism, 
are best studied in an animal model. For the future generation of Trim37 knock-out 
mice, the mouse Trim37 gene (NM_197987) was characterized in detail.  
As expected from the high homology at the protein level, the mouse gene is 
highly homologous to the human gene, with the cDNA sequences showing 88% 
identity between human and mouse.  
Alignment of the mouse Trim37 cDNA sequence to mouse genomic sequence 
revealed identical genomic structure with the human gene. The exon-intron 
boundaries, at identical positions with the human gene, and the sizes of the exons and 
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Figure 10. Alignment of human, mouse, chicken and zebrafish TRIM37 proteins.  
High evolutionary conservation is seen among all species. Especially the amino-terminal part 
of the protein with the functional TRIM (aa 5-254 for human TRIM37) and TRAF (aa 271-
405 for human TRIM37) domains show high conservation.  
 
 
RESULTS AND DISCUSSION  61   










1 418  GAGTGTGGAGgtgaggggca 1 2.2 
2 102 ttgttttcagAGCATTGCTG CTGTATTAGGgtaagttgta 2 7.7 
3 41 gcctccttagCGCTGGCTGA CTCACTGTCGgtaagtgttt 3 2.9 
4 117 ttcttttcagTGCTCCACTC AGAAAGACAAgtgcgtagtt 4 2.5 
5 88 taatgaatagATGTGAAAAT GGGAGGAATGgtgagcagaa 5 2.2 
6 123 atttctgtagCATGGTGGAC TCAAGAAGTGgtaagattac 6 1.3 
7 124 tatcttctagGAAAGAAATG ACTCTCATGGgtgagtgtgc 7 2.2 
8 68 ttttaaacagGTCAGAAGAC AGAACATCAGgtgataaat 8 10.5 
9 125 cctcacacagTTGCGGTCTT ACTTTACCAGgtaacagttt 9 3.9 
10 51 ttctttttagTGAATTGGTA AGAACTTCAGgtaagaggtt 10 2.7 
11 82 ttttctgtagCACTTTGCGG AGTTTACCCAgtaagttttt 11 0.8 
12 77 tttttttaagGATGGAAATG AAACTTCCAAgtaagtgatt 12 10.3 
13 180 tgcattttagGTATGAATAT TGATTTTAAGgtagtttgag 13 4.4 
14 115 attctttaagGTTTCAGGTG TCTTAAAGAGgtaaggcaat 14 2.3 
15 219 attttaaaagAGACTGACTA AGACTATCATgtaataagag 15 1.3 
16 137 ttccttgtagCATGAGCTCT AGGAGACCATgtgagtcccca 16 3.6 
17 86 ctatttgcagGTCTGGGGAA GGTCCTCCAGgtacagaggc 17 6.6 
18 195 tcttttgcagGTAGTAGCCA CAGCCCACAGgtaaaataat 18 4.3 
19 309 ctttttgaagCATCATATTC ATACGAAACCgtaagtgacg 19 4.3 
20 123 tatttttcagCCACAAATAA CTGGCTGAAGgtaaagctga 20 0.7 
21 190 tttcctgaagGCTCCTCGGG TCACCTTGGGgtaaataata 21 2.8 
22 119 cttctttgagGACTAATGCA CCTGAGGAAGgtgagcattg 22 6.6 
23 111 ttcctgccagGAATGAGTAG GAGGTGGAAGgtaattgcca 23 1.7 
24 79/>2431* tttttcttagATTCACATTC GAGGTGGAAGgtaattgcca 24 32.3 
25 >281 ccctctctagACTGCTTGTT    
*Two forms of exon 24 representing alternative splice variants are presented 
 
The sequences of the 5’ flanking regions of the human and mouse Trim37 genes also 
show high homology (Publication III; Figure 2). Several common putative 
transcription factor binding sites are present in human and mouse sequences and basal 
promoter activity is predicted to be present in this region in both species.  
 
3.2.1 Alternative splice variants (IV) 
As human TRIM37 shows a wide range of alternative splice variants, we wanted to 
see whether the same was true also for the mouse gene. Northern analysis with several 
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different probes from the Trim37 coding region revealed three alternative mouse 
transcripts of 3.5, 4.5 and 5.5 kb (Publication IV; Figure 1), whereas the human 
TRIM37 gene shows only two alternative variants in Northern analysis (Publication 
III; Figure 4). To characterize these three transcripts and to find out whether they 
represented the same alternative variants we saw in the human transcriptome (section 
1.2), in silico analysis of database sequences and RT-PCR experiments on mouse 
mRNA were performed.   
A blast search of mouse ESTs returned over 300 mouse Trim37 sequences, 
representing eight alternative variants (listed in Table 11). As the human gene has a 
variant with an additional 3’ exon, we looked especially for a similar transcript in 
mouse. Interestingly, mouse also showed a transcript with 25 exons (Trim37b), with 
the splice site at the identical position as in the human gene. However, while in 
humans the two major transcripts encode identical protein products of 964 amino 
acids, mouse Trim37b has 47 extra C-terminal amino acids, producing a 1008 aa 
protein, while mouse Trim37a produces a 961 aa polypeptide. Among the transcripts 
representing Trim37a (24 exons), several ESTs showed utilization of two alternative 
polyadenylation signals with polyA tracks 1145 and 2348 nucleotides downstream of 
the termination codon. RT-PCR and sequencing confirmed these alternative 3’ 
sequences for mouse Trim37.  
 
Table 11. Alternative mouse Trim37 transcripts from database ESTs 
Nucleotide numbering starts with +1 at the A of the ATG translation initiation site (nucleotide 
398 in NM_197987)  
EST clone(s) Difference to NM_197987 Predicted protein product 
XM_109795 
BU583805 
Trim37b 1008 aa TRIM and TRAF intact 
CN533816 
CN676751 
del part of exon 8 (c.673_684) 
 
957 aa TRIM and TRAF intact 
CD807942 del exon 20  920 aa TRIM and TRAF intact 
CF749419 del exon 19 858 aa TRIM and TRAF intact 
AB093271 del part of exon 9 (c.685_698) 228 aa PTC* 
CF726590 del exons 7-13, parts of exons 6 and 14 (c.418_1222) 164 aa PTC 
CB519726 del exon 3 62 aa PTC 
*PTC = premature termination codon 
 
Based on the EST sequences and human transcripts we hypothesized that the three 
transcripts seen in northern analysis could be explained by different 3’ sequences; as 
the coding region and the 5’ UTR together sum up to 3.3 kb, Trim37a with two 
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different polyA signals could account for the 4.5-kb and 5.5-kb transcripts and 
Trim37b for the 3.5-kb transcript. This was proven to be true, as a Trim37a 3’ UTR 
specific probe detected the 4.5 and 5.5-kb transcripts, with high expression for the 
4.5-kb transcript in testis and the 5.5 kb-transcript in brain, and only the 3.5-kb 
transcript, with high expression in testis, was seen when a Trim37b specific probe was 
used (publication IV; Figure 3). Apart from these three major variants, six other 
alternative transcripts were detected in mouse. The exon 23 deletion seen in human 
splice variants was not among them. Nor was the del23 variant seen in RT-PCR 
experiments on mouse tissues, whereas it was readily amplified from human mRNA. 
As in humans, most of the alternative splice variants seem to be expressed at low 
levels in the mouse, and the same variants could not be detected in humans. 
Alternative variants were also searched from rat databases, and the only variants seen 
in the rat were the Trim37a and Trim37b transcripts, with rat Trim37b producing a 
similar longer protein product as mouse Trim37b. These results further suggest that 
the variants alternating in their 3’ sequences are the major functional alternative 
transcripts of Trim37. Alternative splicing seems to have a regulative role in 
controlling the expression of Trim37, and the other transcripts are likely to be 
produced for this purpose.  
 
3.3 Expression of Trim37 in mouse tissues (IV) 
The detailed expression pattern and distribution of Trim37 expression in embryonic 
and adult mouse tissues was further studied by immunohistochemical methods. 
Antigen affinity-purified fractions of the anti-human TRIM37 antisera (Kallijärvi et 
al., 2002) were used for the detection of Trim37. 
 
3.3.1 Expression of Trim37 in embryonic tissues (IV) 
The distribution of Trim37 expression in embryonic tissues, showed a highly similar 
pattern to the previously reported mRNA expression (Lehesjoki et al., 2001). A weak 
staining was seen already at the earliest stage analysed (E9) and at later stages (E10 
and E12.5) a stronger staining became apparent in many tissues. The staining was 
highest in heart, somites, developing lung and foregut. Strong staining was also 
detected in the surface ectoderm of the embryo. At E15.5 strong staining was seen in 
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the epithelia of intestine and kidney. Also, the developing pancreatic buds, the surface 
ectoderm and the dorsal root ganglia stained intensively.   
 
3.3.2 Expression of Trim37 in adult tissues (IV) 
Adult mouse tissues showed a strikingly restricted and tissue-specific expression of 
Trim37. All tissues of the mulibrey acronym (muscle-liver-brain-eye) stained 
positively (Figure 11; uppermost panel). Relatively weak, fiber-specific distribution 
of Trim37 was seen in a subset of muscle fibers of both skeletal and heart muscle, 
while the ganglia that innervate the muscle tissue showed strong expression. As mild 
hypotonia is the only muscle related manifestation in mulibrey nanism patients, it is 
plausible that, as suggested previously (Karlberg et al., 2004a), the muscle hypotonia 
is related to mild neurological dysfunction. In the liver, weak nuclear staining of 
Trim37 was seen in hepatocytes.  
Strong expression of Trim37 was observed in neuronal tissues. Many regions 
of the brain showed staining in restricted neuronal populations. Mulibrey nanism 
patients have normal intelligence, but mild structural defects are present in the central 
nervous system (CNS) and the patients manifest mild neurological defects, including 
mild delay in motor and speech development and mild muscle hypotonia  (Karlberg et 
al., 2004a). Overall, the immunohistochemical findings in the CNS would suggest a 
stronger neurological defect than what is seen in the patients. Yellowish dots in the 
retinal mid peripheral region are one of the major diagnostic criteria for mulibrey 
nanism (Karlberg et al., 2004a). However, despite the intense photorecepter specific 
expression of Trim37 seen in the retina, the vision is not affected in mulibrey nanism 
patients.  
 Strong Trim37 expression was detected in many tissues of the digestive 
system, including the mucinous tissue of salivary glands, mucus-producing goblet 
cells of the intestine and the enteric ganglia (Figure 11; middle panel). Interestingly, 
many mulibrey nanism patients suffer from poor feeding during infancy (Karlberg et 
al., 2004a). In the light of the expression pattern of Trim37 in the digestive system, it 
would be tempting to speculate that the feeding difficulties could be related to enteric 
ganglia regulated functions i.e. bowel movements or mucus secretion by goblet cells.  
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Figure 11. Immunohistochemical analysis of Trim37 distribution in mouse tissues. 
All tissues of the mulibrey acronym stained positively for Trim37. Skeletal muscle (A) shows 
fiber-specific staining, in the liver (B) weak nuclear staining is seen in the hepatocytes, in the 
brain stem (C) a subset of neurons stain strongly and strong staining is seen in the 
photoreceptor layer of the retina (D). Many tissues of the digestive system show high 
expression of Trim37. The epithelia of the oesophagus (E) and stomach (F) stain positively, in 
the ileum (G) goblet cells stain strongly and in the colon (H) the enteric ganglia stain strongly. 
Some endocrine tissues also stain positively for Trim37. The adrenal medulla (I) shows very 
intense staining and a distinct staining is seen in the islets of Langerhans in the pancreas (J). 
In the gonads strong staining for Trim37 is seen in the germ cells. In testis (K) developing 
sperm stain strongly and in the ovary (L) a subset of maturing oocytes stain strongly. 
Magnification is 200X and 1000X in the insets. 
 
Several endocrine organs showed intense staining of Trim37 (Figure 11; lowermost 
panel). Strong expression was evident in a subset of cells of adenohypophysis, the 
endocrine part of the pituitary gland, and adrenal medulla. Weak staining was also 
present in the endocrine component of the pancreas, i.e. the islets of Langerhans.  
In post-pubertal mice, intense staining for Trim37 was seen in germ cells 
(Figure 11; lowermost panel). In testis, the developing sperm showed strong stage-
specific staining from type B spermatogonia to early round spermatids. In ovaries 
strong staining of oocytes was seen, and also the granulose cells, luteal gland and the 
epithelium of the fallopian tube stained positively. Female mulibrey nanism patients 
present incomplete sexual maturation and develop premature ovarian failure 
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(Karlberg et al., 2004b). In male patients, testicular hypoplasia and reduced number of 
sperm is encountered (Lipsanen-Nyman, 1986). Thus, the immunohistochemical 
findings in mouse gonads are in agreement with the clinical findings of mulibrey 
nanism patients. 
Taken together, these data suggest a role for Trim37 in many neural crest-
derived tissues, as well as in a subset of endocrine tissues and the gonads. The 
expression of Trim37 in mouse tissues is in agreement with the clinical findings in 
human patients. This data, together with the characterization of the mouse Trim37 






CONCLUSIONS AND FUTURE PROSPECTS 67   
CONCLUSIONS AND FUTURE PROSPECTS 
 
In this study the TRIM37 gene was characterized in detail and mutations underlying 
mulibrey nanism were identified and characterized. In general, this thesis work forms 
the basis for the molecular diagnostics of mulibrey nanism as well as for the study of 
the molecular pathogenesis behind this disorder. 
Clinical diagnosis of mulibrey nanism can sometimes be difficult and 
molecular genetic confirmation can be offered to confirm the diagnosis. Most of the 
Finnish mulibrey nanism patients are homozygous for the Finnish major mutation 
while the three minor mutations, identified in four Finnish patients, are seen only in 
compound heterozygous form with the major mutation. Thus, for molecular 
diagnostics in Finland, screening for the major mutation seems to be sufficient and 
other mutations should be looked for only in clinically affected patients heterozygous 
for the major mutation. Elsewhere in the world, private sporadic mutations underlie 
mulibrey nanism and for diagnosis of non-Finnish patients the whole TRIM37 gene 
should be sequenced. 
 In this study, several patients with short stature and some mulibrey-like 
features, but who did not fulfill the diagnostic criteria for mulibrey nanism, were 
screened for TRIM37 mutations, but no changes could be detected. Thus, TRIM37 
mutations seem to be associated only with the distinct clinical phenotype of mulibrey 
nanism (Karlberg et al., 2004a). 
Most of the TRIM37 mutations underlying mulibrey nanism result in PTCs 
and thus are likely to trigger NMD and lead to degradation of mRNA. Consequently, 
little or no protein is produced and the mutations act as loss-of-function alleles. Since 
no genotype-phenotype correlation is seen in mulibrey nanism patients, all mutations 
seem to produce loss-of-function alleles. Thus, the four TRIM37 mutations that are 
likely to express mutant proteins may turn out to be important in assessing the 
function of TRIM37, as they affect important functional domains of TRIM37. These 
mutations either alter the subcellular localization of TRIM37, possibly by affecting 
the interaction properties of TRIM37, or decrease the ubiquitin ligase activity of 
TRIM37, suggesting that both the ligase activity and the peroxisomal localization are 
needed for the proper function of TRIM37. 
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The normal physiological function of TRIM37 is as yet unknown. However, 
since the ubiquitin E3 ligase activity suggests a role for TRIM37 in proteasomal 
protein degradation, the loss-of TRIM37 function may lead to the accumulation of its 
yet unidentified substrates. The identification of these substrates would be valuable as 
it could elucidate the pathogenesis behind mulibrey nanism.  
Expression of TRIM37 seems to be controlled at several levels. The promoter 
region is typical for a house-keeping gene and TRIM37 mRNA is present in all tissues 
but the level of expression varies between different tissues and a specific splice 
variant is present at least in testis. The existence of several seemingly non-functional 
splice variants implies that TRIM37 expression is regulated translationally. This idea 
is further supported by the strictly cell specific protein expression pattern of TRIM37. 
The cell specific distribution of TRIM37 expression also suggests cell specific 
functions for TRIM37. Characterization of this expression pattern in mouse tissues 
may give clues for dissecting the clinical phenotype of mulibrey nanism as well as for 
the pathogenetic mechanisms behind the disorder.  
Despite the current information on the TRIM37 gene and protein, the 
biochemical pathways behind mulibrey nanism are still unknown and many important 
questions remain to be answered. The generation of Trim37-/- mice, which is currently 
underway, opens up new possibilities for the study of Trim37 and mulibrey nanism. 
The high homology between human and mouse Trim37 makes the mouse a promising 
candidate organism to model mulibrey nanism, but whether the mice will replicate the 
human phenotype remains to be seen. However, the knock-out mice will provide an 
unlimited repository of affected tissues and cells, as well as an opportunity to study 
the pathogenetic mechanisms at the level of a whole organism. Mulibrey nanism 
affects several different tissues and developmental processes, growth and cellular 
metabolism. Thus, the Trim37-/- mice may also provide ways to study development 
and growth in general as well as serve as a model for diabetes and metabolic 
syndrome.  
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